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Development and Implementation of an Anthropomorphic Pediatric 
Spine Phantom for the Assessment of Craniospinal Irradiation 
Procedures in Proton Therapy 
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Supervisory Professor: Stephen F. Kry, Ph.D. 
 
Proton therapy is gaining acceptance as a cancer treatment modality, as it allows for 
dose deposition to the target volume while sparing the surrounding healthy tissue. This 
technique is advantageous for craniospinal pediatric patients, as it reduces the radiation side 
effects that can occur. The purpose of this study is to design an anthropomorphic pediatric 
spine phantom for use in the evaluation of proton therapy facilities for clinical trial participation 
by the Imaging and Radiation Oncology Core (IROC) Houston QA Center. It was hypothesized 
that the designed phantom would evaluate patient simulation, treatment planning and delivery, 
assuring agreement between the measured and calculated doses within 5%/3mm, with 85% of 
pixels passing criteria for gamma analysis and also a TLD point dose agreement within 5%. 
Tissue equivalency was determined by measuring the relative stopping power and Hounsfield 
unit of potential phantom materials. The materials selected as bone, tissue, and cartilage 
substitutes were Techron HPV Bearing Grade (RSP 1.3, HU 595.6), solid water (RSP 1.004, 
HU 16), and blue water (RSP 1.07, HU 86), respectively. The design also incorporates two 
thermoluminescent dosimeter (TLD)-100 capsules and radiochromic film embedded for dose 
evaluation. CT images of the phantom were acquired and used to create passive scattering 
and spot scanning treatment plans. Each plan was delivered three times at a dose of 6 Gy. The 
following attributes were evaluated: absolute dose agreement, distal range, field width, junction 
match and right/left dose profile alignment. The hypothesis was accepted for the passive 
scattering plans, making this phantom and delivery technique suitable for use in IROC Houston 
proton approval process.  
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Chapter 1 
1  Introduction and Background 
1.1  Statement of Problem  
1.1.1  General Problem Area 
As proton therapy becomes a more widely used modality for cancer treatment, it is 
important to ensure that treatments at institutions across the country are consistent and 
comparable. For National Cancer Institute (NCI) funded clinical trials using radiation therapy, a 
large number of institutions are required to participate and enroll patients in order to accrue 
sufficient numbers of patients to meet the statistical requirements of the study. Therefore, an 
independent quality assurance (QA) program is required to assure that the prescribed radiation 
doses delivered at multiple institutions are clinically equivalent and reliable.  Even though 
proton-beam therapy facilities may already have their own comprehensive quality assurance 
program in place based on accelerator type, delivery techniques, and recommendations from 
the International Commission on Radiation Units and Measurements (ICRU)[1], a QA program 
that ensures comparability from one facility to the next is still needed. The differences in 
procedures and technologies at each facility can cause challenges in determining the 
consistency in dose delivered to patients treated at various facilities [2]. Currently, there are 
very few organizations that are active in the correlation and assessment of QA procedures, 
along with credentialing across institutions involved in clinical trials using radiation therapy [2]. 
The Imaging and Radiation Oncology Core Houston QA Center (IROC-H), formerly 
known as the Radiological Physics Center (RPC), is a QA group housed at MD Anderson 
Cancer Center in Houston, TX, funded by NCI for the purpose of auditing and credentialing 
institutions for clinical trial participation [3]. This responsibility includes the assessment of 
institutional radiation therapy programs to ensure not only that the administered doses and 
2 
 
results from the clinical trial can be reliably interpreted, but also that dose uncertainty is 
minimized. To achieve this, IROC Houston conducts remote audits of machine outputs, reviews 
of patient treatment records, on-site dosimetry reviews and credentialing of institutions using 
anthropomorphic QA phantoms [3]. These anthropomorphic phantoms are used in the remote 
audit mailable program to verify dose delivery for a variety of advanced technology treatment 
techniques. The data received is analyzed and used to assist the institution in identifying 
discrepancies in the beam modeling of their treatment planning system, dose calculation and/or 
delivery, and to implement resolutions. IROC Houston monitors all conventional radiation 
therapies and has numerous phantoms for photon and electron therapies, such as the 
stereotactic radiosurgery head, spine, thorax/lung, pelvic/prostate, intensity-modulated 
radiation therapy (IMRT) head-and-neck, and liver phantoms [4-6]. In addition to the photon 
phantoms, there are also a family of phantoms for evaluating proton therapies, such as the 
prostate, head, spine, and lung phantoms [7, 8]. In an effort to make these anthropomorphic 
proton phantoms more “proton equivalent” in terms of the tissue simulating plastics, the proton 
spine phantom was found to have deteriorated significantly over the years such that the bone 
within was more like air cavities rather than bony material. Because of these issues with the 
proton spine phantom, a solution had to be found that addressed the problems. 
1.1.2  Specific Problem Area 
 Radiation therapy and the techniques used for controlling cancer have continued to 
expand over the years. Conditions such as prostate, lung, head and neck, and pediatric 
cancers are not only a treated with conventional radiation therapies, but also with proton 
therapy. Facilities nationwide are showing interest in updating their radiation oncology practices 
to include the use of protons. According to the National Association for Proton Therapy, there 
are 16 proton centers in operation, 8 centers under construction and 12 centers currently being 
developed in the United Sates [9]. Therefore, there is an increased need for the evaluation of 
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the radiation treatments delivered to patients using this form of therapy, especially if the 
institution wants to be considered for participation in a cooperative study group-sponsored trial.  
 Currently, IROC Houston has a proton approval process, as mandated by NCI 
guidelines, that institutions must successfully complete before being allowed to enroll patients 
in a clinical trial [10]. This process entails completion of a proton facility questionnaire, annual 
irradiation of dosimeters for verification of proton beam calibrations, verification of the ability to 
transfer patient treatment plans electronically, irradiation of 2 baseline anthropomorphic proton 
phantoms (prostate and spine), and completion of an on-site review at least 6-months after 
routine treatments begin [10]. At this time, IROC Houston has a proton spine phantom that is 
sent to institutions for irradiation. However, the current physical state of the phantom has 
caused problems with the analysis. The skeleton inside the phantom is deteriorating, causing 
air pockets that can lead to inaccurate irradiation conditions associated with matching spine 
irradiation fields. The design of the current spine phantom also causes curvature of the film 
when positioned, causing additional difficulties in the dosimetry analysis since the film fell 
outside of the primary treatment planes (sagittal, coronal and axial). Additionally, the vertebral 
bodies are much larger compared to a typical pediatric patient. Therefore, the goal of this 
project is to design a new more realistic anthropomorphic pediatric proton spine phantom 
based on materials that are tissue equivalent in a proton beam while incorporating the spinal 
curvature in a manner that does not affect the film dosimetry.  This new anthropomorphic spine 
phantom will benefit proton therapy as an independent auditing and credentialing tool. With 
institutions proving their ability to successfully irradiate this phantom, it suggests that treatment 
deliveries to the patient will also be successful. 
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1.1.3  Importance of Topic 
 One of the most common cancers in pediatric patients is medulloblastoma, a brain 
tumor that is known to metastasize through cerebrospinal fluid pathways. While there has been 
increased survival in patients with this disease, there is still a concern regarding the side effects 
associated with craniospinal (CSI) treatments [11]. Beam delivery studies comparing CSI 
treatments have shown that proton beams deliver a more conformal dose to the target 
compared to photon beams [12]. This advantage does not come without uncertainties in the 
treatment process, hence the need for QA procedures and approval processes for clinical trials.  
 Quality assurance programs are designed to verify that the dosimetry conditions 
determined during beam commissioning have not deviated from their baseline values thus 
ensuring that the dose prescription and delivery is fulfilled as intended, while minimizing 
personnel exposure and dose to normal tissue[13]. Recommendations from ICRU 78 for proton 
QA procedures include daily, weekly and annual/scheduled inspection checks for both passive 
and scanning beam-delivery systems [1]. Checks for scattered beam-delivery systems include 
aperture alignment, range, entrance dose, uniformity of range modulation and Bragg-peak 
width, dose monitor calibration according to TRS-398 protocol, checks of monitor unit (MU) 
values, beam-line apparatus, computed tomography (CT) Hounsfield number calibration and 
comprehensive tests of therapy equipment [1]. Additional checks for scanning beam-delivery 
systems include dose rate and monitor ratios for the pencil beam, depth-dose curve of a pencil 
beam in a water phantom and checks of the beam characteristics [1]. For multi-institutional 
clinical trials, one of the key issues is that the QA program vary between proton-beam facilities 
due to differences in the proton accelerator and beam-delivery techniques. This variation, along 
with the implementation of new technology, increases the possibility for error in treatments and 
variability in patient dose delivery between proton facilities if QA checks are not conducted 
appropriately.  
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Quality assurance has always been an important aspect in radiation therapy, but media 
attention has shined a negative light on the field due to radiation therapy accidents. An article in 
the New York Times in 2010, while exposing a fatal treatment error, reported on the RPC’s 
ability to uncover mistakes that can ultimately affect the treatment delivery [14]. With more 
proton facilities being constructed, the mission of IROC Houston has become increasingly more 
important. IROC Houston provides an independent measurement and evaluation of treatment 
planning and delivery as a second check to internal on-site measurements. This independent 
end to end QA measurement can be completed using an anthropomorphic QA phantom 
designed specifically for proton therapy.   
1.2  Hypothesis 
 An anthropomorphic pediatric spine phantom can be designed to evaluate craniospinal 
proton therapy procedures (patient simulation, treatment planning, and treatment delivery) to 
assure agreement between the measured and calculated doses within ±5%/3mm, with ≥85% of 
pixels passing criteria for gamma analysis and a  thermoluminescent dosimeter (TLD) point 
dose agreement within ±5%. To test hypothesis, the following specific aims were developed for 
this project: 
1. Create a suitable spine phantom design based on patient characteristics and 
appropriate proton tissue equivalent materials for corresponding relevant patient 
anatomy. 
2. Image the spine phantom and create clinically relevant treatment plans for both passive 
scattered and spot scanned proton beams.  After the treatment plans are created, 
irradiate the phantom using these treatment plans. 
3. Measure the delivered dose distributions and dose to designated points in the irradiated 
phantom. 
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4. Compare the measured doses and 2D dose distributions to those calculated by the 
treatment planning system to determine the agreement and/or variability. 
1.3  Proton therapy 
1.3.1  Background Information on Protons 
The advantages of using protons for medical purposes were first shown by Robert 
Wilson in 1946. Wilson published the idea of using the energy deposition at the end of the 
proton range, called the Bragg peak, for treating cancer [15]. The Bragg peak, as shown in 
figure 1.1, is a feature on the proton depth dose curve, which plots the specific ionization of 
protons, consequently dose, as they penetrate through depths in tissue. The ionization density 
is relatively low at the surface and also throughout the depth of penetration. However, there is a 
narrow region where the ionization density increases before sharply decreasing, leaving 
negligible dose deposited beyond this region [16]. Other characteristics that give rationale for 
using protons for radiation therapy include: the ability to manipulate the proton range in objects 
based on the density of a material and the energy of the beam, and achieving a more 
conformal dose to the target, leading to reduced tissue complications and increased tumor 
control compared to other conventional therapies [16, 17]. Wilson also introduced the concept 
of using a modulator wheel of varying thickness between the source and the patient to widen 
the region of high ionization density, which is now defined as the spread out Bragg peak 
(SOBP) [15].  This flat dose region still has a rapid fall off in dose beyond the proton range, but 
the SOBP allows for full coverage of larger targets. Both the Bragg peak and the SOBP in 
comparison with photon and electron percentage depth-dose (PDD) curves are shown in 
Figure 1.1.  
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Figure 1.1: Percentage depth dose curves for 6MV photons, 9 MeV Electrons, 160 MeV 
protons with a pristine Bragg Peak, and 160 MeV protons with a spread out Bragg Peak 
 
Protons mostly interact through collisions with atomic electrons in a medium as they 
lose energy. The density of the material and the proton beam energy determine the stopping 
power. The proton mass stopping power describes the amount of energy lost in each 
interaction and is defined as [18]: 
𝑆(𝐸)
𝜌
=  
1
𝜌
𝑑𝐸
𝑑𝑥
,  Equation 1.1 
where S is the linear stopping power which is a function of the energy, dE is the mean energy 
lost as the proton transverses a medium over a distance dx with a known density ρ. The range 
of the proton can be determined from the linear stopping power and is defined as [18]:  
𝑅 =  ∫ 𝑆(𝐸)−1 𝑑𝐸.        Equation 1.2 
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In the stopping interaction, as more momentum is transferred to the electron, the proton stays 
in its vicinity as it loses energy and deposits dose. Therefore, the proton range is proportional 
to the square of the velocity and the stopping power is inversely proportional to the square of 
the proton’s velocity [17].  
1.3.2  Radiation Biology of Protons 
Protons and other heavy charged particles show an increased biological effect 
compared to photons and electrons which can be described by the relative biological 
effectiveness (RBE). The RBE is defined as: 
                      𝑅𝐵𝐸 =  
𝐷𝑜𝑠𝑒𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑟𝑎𝑑𝑖𝑎𝑡𝑖𝑜𝑛 
𝐷𝑜𝑠𝑒𝑡𝑒𝑠𝑡 𝑟𝑎𝑑𝑖𝑎𝑡𝑖𝑜𝑛
.             Equation 1.3 
Equation 1.3 shows the doses needed between a reference radiation, such as 250 kVp x-rays 
or 60Co photons, and a test radiation, to achieve the same biological effect. Experimental data 
is consistent with an RBE of 1.1 for protons [19]. When the RBE is greater than 1, an increase 
in the amount of biological damage to tumors is observed compared photons and electrons that 
have an RBE of 1.   
 To account for the RBE, the weighted proton dose is expressed as Cobalt Gray 
Equivalent (CGE) and is defined as [19]: 
𝐷𝑅𝐵𝐸 = 𝐷 ×  1.1,          Equation 1.4 
where DRBE represents the RBE-weighted absorbed proton dose and D represents the proton 
absorbed dose. According to NCI guidelines, institutions participating in clinical trials must 
report dose prescriptions in units of CGE [10].  
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1.3.3  Proton Therapy Beam Delivery Methods 
1.3.3.1  Proton Accelerators 
 One of the main components of a proton facility is the accelerator used to create the 
proton beams. There are 2 kinds of proton accelerators: cyclotrons and synchrotrons. 
Cyclotrons accelerate particles from a hydrogen source through the gap between pole pieces 
of a large magnet with a fixed magnetic field and a fixed radiofrequency [18]. Classical 
cyclotrons would only accelerate protons up to 10-15 MeV, due to the relativistic increase in the 
proton mass causing problems in accelerating past this energy. Isochronous cyclotrons 
compensate for the relativistic increase by increasing the magnetic field as the radius increases 
to maintain resonance, allowing for protons to be accelerated to a therapeutic energy of 230 
MeV [18]. Because cyclotrons output a fixed energy beam, the range of the beam is shifted by 
placing absorbers or modulation wheels in the beam path[16].  
 The MD Anderson Cancer Center Proton Therapy Center-Houston (PTC-H) uses a 
synchrotron to create the proton beam lines. Synchrotrons accelerate low energy protons that 
are injected into a ring of magnets. These magnets have a fixed radius, allowing the path of the 
protons to repeatedly travel the same path while the magnetic field increases to keep a fixed 
orbit. Unlike cyclotrons, energy variation of the beam can be achieved in addition to range 
shifting [18].  Relevant parameters for choosing an accelerator include the needed speed of the 
energy change, the accuracy of the obtained energy (range), and beam intensity, energy 
spread and beam broadening [17].  
1.3.3.2  Passive Scattering 
 Passive scattering is a method of beam delivery used to spread out near-
monoenergetic protons and create dose distributions for targets. To create a uniform 
distribution, the primary beam is spread laterally using a scattering foil, then degraded to the 
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appropriate energy using a range modulation wheel and possibly an energy absorber, and 
laterally conformity to a target is achieved using apertures and compensators. Beams must be 
double scattered to adequately achieve beam flatness, since a single scattered beam only has 
appropriate flatness in the center of the distribution [17].  
An aperture is a patient-specific device made of brass or cerrobend to shape the beam 
in the lateral direction and stop protons that lie outside the shape of the target. Additional 
margins accounting for setup uncertainties and penumbra are also included in its shape. A 
compensator is placed after the aperture to shape the beam distally by removing variation in 
depth due to the lateral positioning [17]. To create the compensator, the water equivalent depth 
at the distal surface is determined and used to determine the range at the deepest point. 
difference between the deepest point and the respective location is used to determine the 
compensator thickness at that location. If the depth is large, a small amount of material is 
added and if the depth is small, a larger amount of material is added to the compensator. The 
correct amount of compensation is achieved only if there is no misalignment between the 
compensator and the target [17]. Therefore, smearing, or incorporating a margin to account for 
compensator misalignment or changes in patient anatomy, must be added to ensure target 
coverage.  
1.3.3.2  Spot Scanning 
 A second delivery method is spot scanning, where pencil beams are applied in discrete 
steps at various positions to create a uniform dose distribution over the target [18]. A proton 
source is applied in a certain position before the beam is terminated and steered to a different 
location and resumed. While steering the beam, the energy and the depth of penetration are 
changed so that a uniform dose is delivered. Spots are appropriately spaced to avoid non-
uniformity. Unlike passive scattering, patient-specific devices, such as apertures and 
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compensators are not typically used. Advantages of spot scanning over passive scattering 
include achieving more dose conformity to the PTV, a reduction in the secondary neutron dose 
and the ability to use intensity modulated proton therapy (IMPT).  
1.3.4 Dose Uncertainties in Proton Therapy 
Errors and fluctuations can occur in many steps of treatment that lead to uncertainties in 
the dose delivery. These uncertainties arise from errors in tumor identification, staging, spatial 
extent, immobilization, dose distribution, assessment methods, dose calculation algorithms, 
and other treatment parameters [20]. Uncertainties in the proton range are of particular 
importance because an incorrect estimate in range translates to inaccurate dose delivery, 
resulting in an under dose of the target or overdose to the adjacent normal tissue. Range 
straggling, or an energy spread at the stopping location, is produced by both the patient and 
the energy absorbers. This can decrease the sharpness of the distal fall off of the proton depth 
dose curve.  To account for variations, the treatments at PTC-H incorporate a range uncertainty 
of 3.5% of the proton beam range plus an additional 3mm [21]. The additional margin of 3mm is 
added to further account for uncertainties in the distal fall off gradient. With many opportunities 
for a mistake, the need for comprehensive QA programs and additional audits is apparent.  
1.3.5  Beam Monitoring Devices 
 Subsystems to the main components of treatment delivery are contained in the nozzle. 
The nozzle, or treatment head, contains components through which the proton beam traverses 
before being delivered to the patient. This element in the treatment delivery monitors beam 
uniformity, alignment and other physical parameters of the treatment beam. There are many 
devices that intercept the beam as it passes through the nozzle, such as the beam profile and 
reference dose monitors that help control treatment delivery [22]. The beam also intercepts two 
ionization chambers that act as primary and secondary dose monitors to measure the number 
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of MUs delivered and terminate the beam after the prescription MU have been delivered. The 
snout is the part of the nozzle that is closest to the patient and holds the aperture and 
compensator. There are variations between the nozzle components used for passive scattering 
and spot scanning due to the difference in treatment delivery. However, both types of nozzles 
have essential components that are important for ensuring a safe treatment delivery. Other 
essential components in the passive scattering delivery system include: range modulation 
wheel combined with first scatter to create the SOBP, second scatterer, range shifter to finely 
degrade the range, and Faraday cup to measure the energy spectrum [18]. Essential 
components of the spot scanning delivery system include: scanning magnets in the x and y 
directions to steer the spot position, spot position monitor, and energy absorber to control the 
penetration of the beam if needed [18].  
1.3.6  Proton Therapy in Craniospinal Treatments 
 As mentioned previously, pediatric CSI is used for treating patients with 
medulloblastoma. This treatment can be performed using conventional photon and electron 
radiation therapies, in addition to proton therapy. There is currently a debate in the radiation 
oncology community regarding how ethically appropriate proton CSI treatments are, as a 
balance between the clinical, geographical and financial conflicts of this treatment must be 
determined[23]. Research has shown proton CSI as superior to photon CSI after comparison of 
treatment plans and of dosimetric data for pediatric patients [11,12, 24]. Treatments using 
photon therapy have the potential to induce late effects as a consequence of out-of-field and/or 
exit dose being delivered to non-target organs such as the heart, lung, and cochlea. Late 
effects that can occur include impaired growth, hearing loss, neuropsychological dysfunction, 
cardiac diseases and secondary cancers [24]. The properties of protons allows the dose to the 
non-target organs to be significantly reduced. Because using protons for CSI is still novel, it will 
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take many years before published data confirms the proposed reduction in late effects and 
secondary cancer incidence compared to photon therapy [25]. 
Chapter 2 
2  Methodology 
2.1     Research Approach 
The methodology that will be used to accomplish each specific aim is as follows: 
1. The Hounsfield units and stopping power will be determined for phantom materials and 
compared to known values of corresponding human anatomy used for proton therapy. 
2. Images of the phantom will be acquired and used to design one passive scattering 
treatment plan and one spot scanning treatment plan with the Eclipse proton planning 
system, according to MD Anderson’s clinical practice. The development of the plans will 
be based on clinical constraints for CSI patients at the Proton Therapy Center-Houston 
(PTC-H) and a radiation oncologist will confirm that constraints have been met.  
3. Radiochromic film and TLD will be placed inside the phantom and will be irradiated a 
minimum of three separate times according to the designed treatment plan. 
4. The 2-D dose distributions and absolute point doses determined from the film and TLD 
measurements will be compared to the calculated points, dose profiles and dose 
distributions from the treatment planning system to determine the dose differences and 
agreement.  
2.2  Phantom Design 
2.2.1  Previous Phantom Design 
IROC Houston has a variety of anthropomorphic phantoms used as dosimetric QA tools 
in the remote audit QA program. These phantoms consist of plastics that mimic biologic 
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tissues, or a plastic shell that is filled with water. All phantoms contain tissue inserts that mimic 
tumors and critical structures in both physical and anatomical compositions.  Heterogeneous 
phantoms are an advantage when monitoring institutions, as they increase the level of difficulty 
of treatment planning and delivery while simulating a patient. IROC Houston currently has five 
phantoms used during the proton approval process or credentialing: an anthropomorphic head 
phantom, spine phantom, prostate phantom, liver phantom and thorax phantom [3].  
The current proton spine phantom used by IROC Houston contains skeletal vertebrae 
cast in a muscle-equivalent material and is a tool for testing beam range verification, along with 
the institution’s ability to properly match two proton fields at a junction [3, 26]. The main 
disadvantage to using actual vertebrae in anthropomorphic phantoms is that, over time, 
crevices and air pockets begin to form within the bone. Additionally, the vertebral bodies in the 
current spine phantom are much larger than pediatric vertebral bodies and are not appropriate 
to evaluate CSI treatments. Therefore, the new spine phantom design was developed to 
overcome these three existing problems: to contain 1) durable biologically equivalent materials 
that will not degrade over time 2) size-appropriate vertebrae for a pediatric patient, and 3) did 
not require bending of the film. These improvements removed the major factors that previously 
lead to difficulties in the use of and dosimetric assessment of proton CSI treatments at 
institutions.  
 
2.2.2  Phantom Design Considerations 
Materials that simulate tissue when placed in a photon beam may not simulate tissue 
when placed in a proton beam. Plastics that are considered photon equivalent are determined 
by the Hounsfield unit (HU) and electron density of the material. In proton therapy, a material’s 
proton equivalency is determined based on the HU and proton stopping power. A material must 
fall within 5% of the HU-stopping power calibration curve of the treatment planning system [27]. 
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Therefore, the phantom should be designed using materials that have been tested and 
confirmed to be accurately mimic a patient in a proton beam. These materials should be 
durable and not only remain intact over time, but also be easily transportable by mail to various 
institutions. Materials chosen should be discernable on a CT image to ensure accurate 
treatment planning. The phantom should be designed to include minimal air gap at the 
interfaces between the bone, cartilage and soft tissue substitutes to avoid introducing additional 
range uncertainty. The phantom should be designed to accommodate placement of both TLD 
and film for dosimetric measurements. The simulated spine curvature should be designed to 
avoid arching in the film. The dimensions of the phantom should be designed to accurately 
represent the spinal column of a pediatric patient and to accommodate the beam divergence 
when using a junction.  
 Clinically, CSI junctions are placed in the thoracic region of the spinal column during 
treatments when needed. Therefore, the thoracic region was selected for simulation in the 
phantom design. The design should incorporate 3 materials that simulate bone, cartilage and 
soft tissue. The inclusion of multiple tissue substitutes increases the treatment planning 
difficulty, resulting in a more realistic patient simulation. Institutions capable of planning and 
conducting a successful treatment using this heterogeneous spine phantom suggest to IROC 
Houston that the institution can appropriately deliver a proton CSI treatment that would require 
junction matching of the two proton fields.  
 
2.1.3 Determination of Bone Equivalent Material 
Because no suitable bone-equivalent material was known to IROC-Houston, potential 
bone substitutes were tested for bone-equivalency in a proton beam. The main characteristic 
considered when determining possible materials was density, as this parameter would largely 
affect the range of the proton beam during irradiations and the HU. The density of bone can 
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vary depending on its location and marrow content. Dense bone has a density of 1.85 g/cm3 , 
according to National Institute of Standards and Technology (NIST) [28]. The density of the 
bone in the vertebral column was reported as 1.33-1.42 g/cm3 in a study by Schneider et. al 
[29]. Therefore, a range in density of approximately 1.3-1.8 g/cm3 was used to compile a list of 
materials for testing. A total of 11 materials were tested as a potential bone substitutes and 
three of the materials were described as photon bone-equivalent by a manufacturer (Gammex, 
Inc., Middleton, WI). A list of tested materials and corresponding densities is shown in Table 
2.1.  
Material Name Density (g/cm3) 
Gammex Inner Bone 1.12 
Gammex Cortical Bone 1.82 
Gammex B200 Bone 1.15 
Boedeker Techron HPV Bearing Grade 1.43 
Boedeker Ketron PEEK GF30 1.51 
Boedeker Polyester PETP Ertalyte TX 1.44 
Boedeker Ketron HPV Bearing Grade 1.44 
Boedeker Polyester PETP Ertalyte 1.41 
Boedeker Duratron T4301 PAI 1.45 
Crayola Clay 0.11 
Concrete block 1.78 
 
              Table 2.1: Composite list of materials tested for bone tissue substitutes 
 
 After obtaining the HU and relative stopping power (RSP) for each potential material, 
this data is plotted along the PTC-H calibration curve. As previously mentioned, to determine if 
a material is patient equivalent for proton therapy, the HU and RSP of a material are compared 
against the treatment planning system’s (TPS) calibration curve. This bilinear calibration curve 
is created using a stoichiometric method, where the measured HU of animal tissues and tissue 
substitutes are used as predictors for the HU corresponding to human anatomy [29, 30].  
 A CT  image of each material sample was acquired on the GE LightSpeed RT16 CT 
scanner (GE Healthcare, Waukesha, WI) at PTC-H using an scan protocol of 120 kVp, 120 
mAs, 48cm diameter field of view and a slice thickness of 5mm [31]. The images were then 
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imported into the Eclipse TPS to determine the HU. The mean HU and standard deviation were 
calculated based on a series of 10 measurements from each sample. Next, depth dose curves 
with each material in the proton beam path were acquired on the fixed passive scatter beam 
line at PTC-H using a modified technique described in Moyers et. al [31].  Each material was 
placed in front of the Zebra multi-layer ionization chamber detector, (IBA, Schwarzenbruck, 
Germany) a device used to measure the depth dose curve. A reference curve was also 
completed without any material present in the beam. All scans were performed with an 18 x 18 
cm field and a SOBP of 10cm to 50 MU. The data from the depth dose curves was used to 
calculate the RSP, described by:  
𝑅𝑆𝑃 =  
𝑅80,𝑤−𝑅80,𝑚
𝑡𝑚
                           Equation 2.1 
where R80, w represents the depth to the distal 80% dose without material present in the beam, 
R80, m represents the depth to the distal 80% dose with material present in the beam, and tm 
represents the thickness of the material sample. The relative stopping power was calculated at 
energies of 160 MeV and 250 MeV. Because most craniospinal treatments use a 160 MeV 
beam, the stopping powers corresponding to this energy were used for determining proton 
equivalency. Results from Grant et. al were used to select the cartilage and soft tissue 
substitutes [27].  
 
2.2.3.1 RSP Error Analysis 
A total of 10 HU measurements were conducted and used to calculate the mean and 
standard deviation for each material to assess the uncertainty of the HU for each sample. The 
uncertainty in each variable from Equation 2.1 was used to determine the uncertainty in the 
relative stopping power calculations. The equation used to calculate the uncertainty in the 
stopping power is given as [31]: 
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𝒅𝑹𝑺𝑷 =  
𝒅𝑹𝟖𝟎,𝒘
𝒕𝒎
+  
𝒅𝑹𝟖𝟎,𝒎
𝒕𝒎
+
|𝑹𝟖𝟎,𝒘−𝑹𝟖𝟎,𝒎|𝒅𝒕𝒎
𝒕𝒎
𝟐      Equation 2.2 
where dR80, w represents uncertainty in the depth to the distal 80% without material present in 
the beam, dR80, m represents uncertainty in the depth to the distal 80% with material present in 
the beam, and dtm represents the uncertainty in the thickness of the material sample. The 
Zebra specifications state that the range accuracy is ±0.5mm and the uncertainty in the 
measured thickness is ±0.1mm.  
 
2.2.4  Phantom Design 
 
The phantom was designed with the considerations described in Section 2.2.2, based 
on the anatomical dimensions of pediatric patients treated with proton therapy at the PTC-H. 
Data was collected from treatment plans of five craniospinal patients, ages 5-11 years old. The 
measurements of the vertebral length, vertebral thickness in the sagittal plane, cartilage 
thickness, distance from the spinous process to the transverse processes on the left and right 
sides, along with the diameter of the vertebral foramen and HU of the various anatomical 
components, were averaged to determine the internal characteristics of the phantom. The 
maximum difference in the distance from the skin to the distal end of the vertebral body was 
used for determining the amount of simulated spinal curvature. Image of the preliminary 
phantom design in the sagittal and coronal planes with corresponding dimensions are shown in 
Figures 2.1 and 2.2. 
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Figure 2.1 Sagittal View Diagram of the Phantom Design 
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Figure 2.2 Coronal and Top views of the Phantom Design 
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2.3  Phantom Experiment 
2.3.1  CT Simulation 
All simulation images were acquired using the GE LightSpeed RT16 CT scanner at the 
PTC-H following the clinical pediatric spine CT protocol. Two double-loaded TLDs, along with 
two film dosimeters in the sagittal and coronal planes, were placed inside the phantom. 
Because these dosimeters would be in place for imaging and treatment, four single-loaded 
TLDs were placed on the exterior of the phantom to measure background radiation signal to be 
subtracted from the interior TLDs.  The phantom was placed on the CT table in the supine 
position. The lasers were aligned to exterior marks delineating the isocenter. Once the scan 
was obtained, these images were then transferred to the Eclipse treatment planning system, 
where the CT couch was removed. The proton treatment couch was inserted into the images 
by a certified medical dosimetrist using in-house DICOM algorithm software. Images of the 
phantom in the axial and sagittal planes are shown in figures 2.3 and 2.4.  
 
 
Figure 2.3: Sagittal CT image of the phantom showing locations of the vertebral bodies, 
cartilage and right superior TLD 
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Figure 2.4: Axial CT Image of the phantom. The film planes are visible as the orthogonal 
black lines through the phantom. 
 
 
2.3.2  Treatment Planning 
The following structures were contoured on the CT images: spine, spinal cord, and body 
contour (including the treatment couch to account for the proton range). The vertebral body 
was designated as the CTV in both the passive scattering and spot scanning treatment plans 
and also used to determine the field parameters. Proton planning is not based on the PTV like 
in photon planning, as it can cause an incorrect dose estimation in the CTV [32]. Proton 
therapy adds additional margins not only in a direction perpendicular to the beam path, but also 
along the direction of the beam path. Because the margin is calculated based on the beam 
range, each field would have different volumetric margins, making the use of a PTV very 
complex. 
A typical dose prescription delivered to the spine during craniospinal treatments and 
can range from 18-36 Gy CGE, but PTC-H uses a prescription of 23.4 Gy CGE [33]. However, 
based on typical IROC Houston requirements, a single dose of 6 Gy CGE was delivered to the 
phantom, to maintain the dose in a range appropriate to be measured with the film. As IROC 
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Houston does not yet have dose constraints for this phantom, the dose constraints for patients 
treated at the PTC-H were used. Specifically, the 6 Gy isodose line was required to cover 
≥95% of the CTV, and all hot spots must be ≤107%.  
Treatment plans were created with the assistance of a PTC-H medical dosimetrist and a 
medical physicist. Digitally reconstructed radiograph (DRR) images were also created to assist 
with localization during the treatment setup. A PTC-H radiation oncologist confirmed that the 
plan was appropriate and clinical constraints were met.  
 
2.3.2.1 Passive Scattering Treatment Plan 
Two equally weighted, posterior-anterior beams were used to create the superior and 
inferior spine fields of the passive scattering plan. The junction was placed in the middle of the 
phantom near the center of the vertebral column, with a 0.5cm gap between the fields at the 
surface of the phantom and a match at approximately 2cm depth in the middle of the phantom. 
The junction was shifted by 1 cm to create a second junction plan. For each field, brass 
apertures and acrylic compensators (Figures 2.5 and 2.6, respectively) were created at the 
PTC-H machine shop. The plan sum of the two junction plans composed the final plan.   
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Figure 2.5: Passive Scattering Brass Apertures 
 
 
   
Figure 2.6: Passive Scattering Acrylic Compensators 
Listed in Table 2.2 are the treatment parameters for the passive scattering plan. Figure 2.7 
shows the isodose distributions in the axial, coronal and sagittal planes.  
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Passive Scatter Treatment Plan 
Prescribed Dose: 600 cGy 
Beam A B C D 
Beam Name Superior 
Spine-
Jxn1 
Inferior 
Spine-
Jxn1 
Superior 
Spine-
Jxn2 
Inferior 
Spine-
Jxn2 
Beam Energy 
(MeV) 
160 160 160 160 
Gantry Angle 180 180 180 180 
Couch Angle 0 0 0 0 
Snout Position 25 25 25 25 
SOBP Width 7 7 7 7 
 
Table 2.2: Passive Scatter Planning Parameters 
 
 
 
 
a)  
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b.)  
c.).  
Figure 2.7: Passive Scattering Treatment plan views in the (a) axial, (b) sagittal, and (c) 
coronal planes.  
 
The gantry was planned and irradiated using the G2 gantry at PTC-H. The monitor units 
for each field were calculated using the following equation: 
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  𝑴𝑼 =  
𝑷𝒉𝒚𝒔𝒊𝒄𝒂𝒍 𝑫𝒐𝒔𝒆
𝑹𝒆𝒍𝒂𝒕𝒊𝒗𝒆 𝑶𝒖𝒕𝒑𝒖𝒕 𝑭𝒂𝒄𝒕𝒐𝒓∗𝑹𝒂𝒏𝒈𝒆 𝑺𝒉𝒊𝒇𝒕 𝑭𝒂𝒄𝒕𝒐𝒓∗𝑺𝑶𝑩𝑷 𝑶𝒖𝒕𝒑𝒖𝒕 𝑭𝒂𝒄𝒕𝒐𝒓
           Equation 2.3 
The parameters used to calculate the MU are listed in Table 2.3. In the treatment plan, each 
field isocenter was located in the penumbra of the field, which is an insufficient position for a 
dose calculation point due to the high dose gradient. Therefore, a verification plan was created 
to determine the dose to the center of the field with the aperture in place. The dose from the 
verification plan was used for the dose calculation. 
 
 
Passive Scatter Treatment Plan 
Prescribed Dose: 600 cGy 
Beam A B C D 
Beam Name Upper 
Spine-Jxn1 
Lower 
Spine-Jxn1 
Upper 
Spine-Jxn2 
Lower 
Spine-Jxn2 
Relative Output Factor 0.827 0.827 0.827 0.827 
Range Shift Factor 0.89 0.89 0.89 0.89 
SOBP Factor 1.162 1.162 1.162 1.162 
Dose to Center of Field cGy-
RBE (from verification Plan) 
313.4 313.4 313.4 313.4 
Physical Dose in cGy 284.9 284.9 284.9 284.9 
MU Calculated 333.1 333.1 333.1 333.1 
Table 2.3: MU Calculation Parameters for Passive Scatter Plan  
 
2.2.2.2 Spot Scanning Treatment Plan 
Similar to the passive scattering plan, two equally weighted, posterior-anterior beams 
were created for the spot scanning plan. This treatment plan was created for irradiation on G3, 
the designated spot scanning gantry at PTC-H. The junction occurs in the middle of the 
phantom with a field overlap of approximately 6cm. Unlike passive scattering, a hand 
calculation of the monitor units was not needed, as the treatment planning system conducts 
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this calculation. Table 2.4 contains the spot scanning treatment delivery parameters and figure 
2.8 displays the isodose distributions for the spot scanning treatment plan.  
Spot Scanning Treatment Plan 
Prescribed Dose: 600 cGy-RBE 
Beam A B 
Beam Name Upper Spine Lower Spine 
Beam Energy (MeV) 146.9 146.9 
Gantry Angle 180 180 
Couch Angle 0 0 
Snout Position (cm) 38 38 
Number of Spots (post-
processed) 
9012 8019 
SOBP Width 7.03 7.08 
MU Calculated by TPS 353.92 314.73 
Table 2.4: Spot Scanning Planning Parameters 
a.)  
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b.)   
c.)  
Figure 2.8: Spot Scanning Treatment plan views in the (a) axial, (b) coronal, and (c) 
sagittal planes.  
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2.3.3  Treatment Deliveries 
 The phantom was set up on the treatment couch and aligned to the primary isocenter 
placed in the middle of the phantom using the lasers. A manual couch shift was used to move 
the phantom to the respective superior and inferior field isocenters.  X-ray images of both fields 
were acquired and compared to the digitally reconstructed radiographs (DRRs) from the 
treatment plan as an assessment and confirmation of the phantom alignment. For the passive 
scattering plan, additional x-ray images were taken with the apertures in place to further verify 
the phantom setup. Tape markings were placed on the phantom and the couch post-alignment 
to assist with repositioning between the disassembly and reloading of the phantom dosimeters. 
Both treatment plans had gantry angles of 180º and couch angles of 0º for all fields. The 
superior spine field was delivered first, followed by the inferior spine field. For the passive 
scatter irradiation, a second junction plan containing both a superior spine field and inferior 
spine field was delivered directly after the first junction plan. The summed dose for these 
passive junction plans was considered as one passive scattering treatment delivery. A 
biologically effective dose of 6 Gy CGE was delivered during each irradiation. Three complete 
phantom irradiations were conducted per treatment technique (passive scattering or spot 
scanning) as a part of a reproducibility study. Once the first irradiation was complete, the 
irradiated film and TLD inside the phantom were removed and the phantom was reloaded with 
unirradiated dosimeters. The phantom was repositioned based on the tape markings and x-ray 
images were quickly acquired to verify the alignment before the next treatment delivery began. 
This process was completed until all three irradiation trials were complete.  
2.2.4 TLD 
2.2.4.1 Point Dose 
 TLD is good for remote dosimetry as it is a passive detector that can be used as an 
absolute dosimeter. The TLDs measure the dose delivered at their respective locations in the 
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right superior and left inferior positions of the phantom spinal canal. Thermoluminescent 
materials contain trapping (F) centers that collect a charge proportional to the dose deposited. 
As the radiation interacts with the TLD, electron-hole pairs are created and may become 
trapped in the F centers between the conduction band and valence band. Heating the TLD can 
cause the release of electron-hole pairs from the traps to conduction and finally, the release of 
the signal as electrons migrate from the conduction band and recombine with holes in the 
valence band [34]. This signal is captured by a photomultiplier tube that counts the amount of 
charge collected. This charge, along with a series of correction factors, is used to calculate the 
delivered dose.  
 IROC Houston uses TLD-100 (Harshaw Chemical Company, Solon, OH), a lithium 
fluoride TLD powder doped with Mg and Ti to create the trapping centers. Approximately 25 mg 
of powder is placed into polyethylene capsules allowing for easy placement into the phantom. A 
previous study has determined that using TLD-100 as a dosimeter for protons with energies of 
100 to 250 MeV produced accurate dose measurements within 5% of the expected dose [35]. 
This conclusion, along with studies by former RPC physicists allows for confidence use of TLD-
100 as a dosimeter for this proton phantom [36]. 
 The delivered dose to the TLD is calculated using the following equation:   
𝑫𝒐𝒔𝒆 = (
𝑻𝑳
𝒎𝒂𝒔𝒔
) 𝒙 𝑺 𝒙 𝑲𝑭 𝒙 𝑲𝑳 𝒙 𝑲𝑬 𝒙 𝟏. 𝟏                           Equation 2.4 
where TL represents the TLD signal in nC, mass is the mass of the TLD powder in mg, S is the 
system sensitivity, KF represents the fading correction factor, KL is the linearity correction factor 
and KE is the energy correction factor. Because TLD measured the physical dose delivered to 
the phantom, the RBE correction of 1.1 must be included in the dose calculation to give the 
biological effective dose.  
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 The signal of the TLD was normalized to the mass of the powder during the readout so 
that differences in the mass were not factored into the dose calculation. The system sensitivity 
factor (dose/signal) is the considered the calibration factor, to account for the dose response 
and change from 60Co reference conditions to proton conditions.  This calibration factor is most 
critical, as it accounts for any variation between readout sessions, such as days since 
irradiation and reader variability, and also relates the charge collected to the dose measured. 
The system sensitivity is calculated by 
                                                      𝑺 =
𝑫𝒐𝒔𝒆
𝑲𝑭 𝒙 𝑲𝑳 𝑿 (
𝑻𝑳
𝒎𝒂𝒔𝒔
)
𝑨𝑽𝑮
                           Equation 2.5 
The system sensitivity calculation uses the calculated fading, linearity and expected dose of the 
TLD standards.   
 Fading occurs when trapped electrons are unintentionally released before the readout 
session occurs. The fading correction for the phantom TLD is calculated using Equation 2.6: 
 𝑲𝑭 =  
𝑵
𝒂𝒆−𝒃𝒙+𝒄𝒆−𝒅𝒙
         Equation 2.6 
where N, a, b, c, and d are coefficients that were determined based on the fading 
characterization previously conducted by IROC Houston. The values of these coefficients will 
be stated in a later subsection. TLD should be read out no sooner than 10-14 days post-
irradiation due to the instability of and rapid change in the fading process.  
 The linearity correction factor accounts for the non-linearity in the TLD response over 
the range of doses used for readout. It is important that the standards are irradiated in a dose 
range comparable to the phantom TLD so that the linearity correction is minimized. Equation 
2.7 states the linearity correction factor equation:   
𝑲𝑳 = 𝒂𝒙
𝟐 + 𝒃𝒙 + 𝒄                     Equation 2.7        
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where a, b, and c are variables determined by IROC Houston during the TLD batch 
characterization, and x is raw dose as determined by multiplying the normalized TLD reading 
by S and KF. 
 TLD has an energy dependence and the change in response due to energy must be 
corrected for if the calibration and experimental TLDs are irradiated at energies different than 
the 60Co reference energy. IROC Houston irradiates the TLD standards using 60Co as the 
reference beam and also has compared the TLD response to the response of TLD at all proton 
energies.  The proton energy correction factor, KE, has been determined to be unity (within 4%, 
with a standard deviation of 2%). 
In order to properly determine the correction factors previously listed, a set of standards 
was irradiated to a known dose as a calibration. The standards were irradiated to a known dose 
of 800 cGy on a Co-60 machine. By irradiating a set of TLD to a known dose, the reference 
conditions needed to determine the correction factors was established.  
During the TLD readout session, first, a set of standards were read, followed by a set of 
controls. Then, 6 irradiation TLD can be read before another set of controls must be read. This 
process of alternating between the readings of irradiation TLDs and controls was repeated until 
all irradiation TLD had been read. The session was closed out by the reading of controls 
followed by standards.  
The TLD batch B11 was used for the phantom. Previous batch characterization by 
IROC Houston staff was completed before the start of this project. Table 2.5 lists the fading and 
linearity corrections factor constants introduced in Equations 2.6 and 2.7, respectively.  
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Fading Correction Constants  Linearity Correction Constants 
N 1.3493  a 2.552065E-08 
a 1.2815  b -2.221104E-04 
b 0.00010885  c 1.064337 
c 0.067810    
d 0.071908    
x # days from irradiation date to reading date    
Table 2.5 Fading and Linearity Correction Factor Constants 
 The TLDs for the passive scatter and spot scanning irradiations were read out 10 days 
and 22 days post-irradiation, respectively. The point dose criteria, as stated in the experiment 
hypothesis, was agreement within ±5%. Therefore, the ratio between the measured TLD dose 
and the calculated TPS dose would have to fall within the range of 0.95-1.05 to meet the 
agreement. To calculate the reproducibility of the experiment, the coefficient of variation was 
calculated and hypothesized to be less than 3%.  
2.3.5 Film Planar Dosimetry 
 Radiochromic film, specifically GAFchromic® EBT2 film (Ashland Inc., Covington, KY), 
was used as the passive detector to observe the dose distribution in the coronal and sagittal 
planes of the phantom. Characteristics of radiochromic film including high spatial resolutions, a 
weak energy dependence over the dose range and radiation beam quality, near tissue 
equivalence, minimum sensitivity to visible light, and the development of film in real time 
without processing makes this a suitable detector for remote dosimetry [37]. The lot number 
used for the entirety of this study was #07301301 with an expiration date of July 2015. A 
diagram of the cross-sectional components of the film from the GAFchromic® EBT2 film 
specifications is shown in Figure 2.9.  
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Clear Polyester Layer (50 microns) 
Adhesive Layer (25 microns) 
Top Coat (5 microns) 
Active Substrate Layer (30 microns) 
Clear Polyester (175 microns) 
Figure 2.9 Cross-Sectional Layer Diagram of GAFchromic® EBT2 film 
2.3.5.1 Film Calibration 
The film batch was calibrated using a passive scatter irradiation technique at PTC-H. 
The irradiation conditions were as follows: medium snout size, 4 x 4 cm aperture field size, 160 
MeV beam energy, SOBP of 10cm, and 8cm of buildup material above and below the phantom. 
The film was cut to a size of 7 x 7cm2 prior to the calibration irradiation. Care was taken to 
ensure that each film was irradiated in the same manner, as EBT2 has a known orientation 
sensitivity and there are inhomogeneities in the scanner [38]. Based on the irradiations from 
previous film calibrations by IROC Houston, the doses chosen for irradiation were: 50, 100, 
150, 200, 300, 400, 500, 600, 700, and 800 cGy. The MU used to irradiate the film at each 
dose level was calculated using Equation 2.3. RBE was not included in this set of MU 
calculations, since the film dose distribution were eventually normalized to the TLD which 
included the RBE. 
The film was placed between slabs of acrylic, with the center of the film set up at 
isocenter, or 270 cm source-to-axis-distance (SAD). The film was irradiated with 160 MeV 
protons, as this is the energy used by our institution to treat pediatric craniospinal patients. The 
dose is specified at the center of the SOBP, which was at a depth of 8cm for a 160 MeV beam 
in a proton snout. The same amount of material was placed behind the film to ensure that the 
beam did not extend beyond the phantom. Figure 2.10 shows a picture of the setup.  
Approximate 
thickness: 
0.3mm 
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Figure 2.10 Film Calibration Irradiation Setup at PTC-H.  
The films needed to be analyzed to determine the optical density (OD) for the creation 
of the dose response (dose vs. OD) curve. Studies have shown that, conservatively, film should 
sit for at least 48 hours before readout to account for any possible fading changes of the film 
[38]. The calibration films in this study were scanned 5 days after irradiation using the CCD 
Microdensitometer for Radiochromic Film Model CCD100 (Photoelectron Corporation, 
Lexington, MA) at IROC Houston. A spatial calibration and flat field adjustment was conducted 
using a blank piece of film from the same batch prior to the scanning of the other films. Three 
OD measurements were taken using the software ImageJ (Rasband 1997-2011) and averaged 
for each dose. A third degree polynomial was fit to the dose vs. OD plot to create the film 
calibration curve. This dose response curve was used for both passive scattering and spot 
scanning irradiations, since studies have shown that the calibration curve for spot scanning 
systems is similar to the curve for passive scattering systems [39, 40].  
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2.3.6 Dosimetric Analysis 
2.3.6.1 CT, Film and TLD Registration 
 IROC Houston uses a MATLAB®-based, in-house developed software, to register the 
scanned film images with the CT structures, images and the composite dose information from 
the treatment plan. The orientation of the film and the TLD locations also need to be registered 
with the data from the treatment planning system. The pin locations in the phantom dictate the 
spatial orientation of the film in both planes relative to the phantom structures. These pin points 
were used as registration locations for the software.  
 To determine the coordinates of the pin pricks relative to the primary isocenter (in the 
middle of the phantom), the distance from isocenter to the respective locations of the pin pricks 
and the TLD placeholders must be determined. This was done using a ruler and a pricked 
piece of grid paper. These coordinates were input into an excel spreadsheet used by the 
program. The CT images were registered to these coordinates after selecting the isocenter to 
be in the middle of the phantom and measuring the distance to all 6 pins. Additionally, the 
coefficients from the OD-dose calibration curve were entered into the spreadsheet so the 
proper dose conversion can be applied. 
 Once the registration information was properly input, the scanned film images can be 
opened in the software. The physical locations of the pin pricks on the film were identified to 
complete the 2D-registration (see Figure 2.11). The error in registration was calculated by the 
software and displayed as root mean square (RMS) to determine the goodness of fit. Next, the 
proper OD-dose curve was selected and the TLD doses in Gy CGE were entered. A correction 
was applied to the film image to convert the displayed OD to displayed dose and to scale the 
dose grid of the film to the measured TLD dose. An example of the selected registration points, 
the OD-to dose conversion and the RMS error is shown in figure 2.15. The composite file 
containing the CT images, contour structures and dose information was then opened with 
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Computation Environment for Radiotherapy Research (CERR). Within CERR, the locations of 
the pins on the CT images were again identified and selected. The in-house software then used 
CERR to complete a 3D-registration of the film and CT images for comparison purposes. This 
is a standard procedure used by IROC Houston to register films from anthropomorphic 
phantoms. The software also calculates an RMS error for 3D registration, which should be less 
than 2mm. 
 
Figure 2.11 Selection of the pin prick registration points on a scanned coronal film 
        
 
Figure 2.12: The displayed RMS error, OD to Dose Conversion and TLD correction in 
MATLAB® 
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2.3.6.2 Gamma Analysis 
 To evaluate the agreement between the 2D dose distributions of the film and TPS, a 
gamma analysis calculation was performed in the in-house software [41]. A dose and distance 
to agreement criteria of ±5%/3mm and ±5%5mm were both used in the comparison. For each 
film plane, a rectangular region of interest was designated for inclusion of the entire dose 
distribution in the calculation.  A mask was applied to regions of the image that should not be 
included in the calculations, such as blank regions of 0 dose acquired by the densitometer and 
regions of high OD values from the pin pricks. As stated in the hypothesis, an 85% pixel pass 
rate was used as part of the gamma analysis criterion.  
 
2.3.6.3 Distance to Agreement  
 Dose profiles were also created in the MATLAB® software program in the right-left, 
anterior-posterior, and superior-inferior directions. A set of the profiles was taken in both the 
superior and inferior spine fields on both film planes. In the anterior-posterior direction, the 
superior field profile is acquired through the bone, while the inferior field profile is acquired 
through the cartilage. This is done for comparison of profile discrepancies between the two 
materials.  The junction matching profiles were acquired in the superior-inferior directions of 
both planes. The cold spot profile was taken in the center of the coronal film, while the hot spot 
profile was acquired toward the anterior edge of the sagittal film. Because the phantom was set 
up supine, the cold spot appeared near the surface of the phantom, while the hot spot occurred 
at depth.  
 These profiles were used to determine the distance to agreement (DTA) between the 
film and the TPS and also the junction match agreement. The DTA measurements were 
calculated in the distal-fall off regions in the right, left and anterior directions. A linear 
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regression was fit to the TPS and film data between the 75% dose and 25% dose thresholds. 
Comparison points of the displacement between the TPS and film were taken at 25%, 50% and 
75% of the dose, in the steep dose fall off region at the edge of the CTV. These displacements 
were averaged on both sides of the profile to determine the DTA. To correlate with the gamma 
analysis criteria, an acceptable DTA would be less than or equal to 5mm. In the superior-
inferior profiles, the spatial shift and dose difference at the junction was evaluated. To 
determine the junction shift at the peaks, the user estimated the peak center location on the 
graph. A function determined in the profile data the closest distance to the user-selected value 
and the corresponding dose at this point. This process was done for both the film and TPS 
profiles. Based on the determined peak centers, the percent difference between the film and 
TPS doses along with the spatial shift between their respective locations is calculated. To be 
deemed acceptable, there should be no more than a 5mm shift. Additionally, the percent dose 
difference between the hot/cold spot peaks should be less than 7%. The percent dose 
difference was chosen to correlate with the criteria from the gamma analysis and TLD, with 
additional margins to account for the increased dose variation at the junction. 
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3  Results/Discussion 
3.1  Phantom Materials 
3.1.1  Relative Linear Stopping Power 
The goal during the phantom design was to incorporate materials that simulated the 
thoracic spinal column of a pediatric patient. A total of eleven potential bone substitute 
materials were tested to determine the relative proton stopping power and Hounsfield unit 
values. Table 3.1 contains the potential materials with their corresponding HU and RSP at 160 
MeV and 250 MeV. Because most craniospinal treatments use a 160 MeV beam, the stopping 
powers corresponding to this energy were used for determining patient proton equivalency.  
Material Name HU ± SD RSP at 
160 MeV 
RSP at 
250 MeV 
Mean 
RSP 
Percent Difference 
(160 vs 250 MeV) (%) 
Gammex Inner 
Bone 
70 ± 30 1.61 1.60 1.61 
 
1.0 
 
Gammex 
Cortical Bone 
843 ± 87 1.09 1.08 1.09 1.3 
B200 Bone 250 ± 17 1.10 1.09 1.10 0.9 
Techron HPV 
Bearing Grade 
596 ± 14 1.30 1.28 1.29 1.3 
Ketron PEEK 
GF30 
604 ± 5 1.41 1.39 1.40 1.4 
Polyester PETP 
Ertalyte TX 
332 ± 20 1.36 1.34 1.35 1.7 
Ketron HPV 
Bearing Grade 
298 ± 21 1.35 1.33 1.34 1.6 
Polyester PETP 
Ertalyte 
272 ± 10 1.30 1.28 1.29 1.8 
Duratron T4301 
PAI 
287 ± 19 1.36 1.34 1.35 1.3 
Concrete 933 ± 
169 
N/A 1.86 1.86 Incalculable 
Crayola Clay 1029 ± 
15 
1.61 1.61 1.61 0.0 
Human 
Vertebrae 
(Average) 
650 
  1.3  
Human 
Cartilage 
(Average) 
110 
  1.1  
 
Table 3.1 Comparison of HU and measured RSP at 160 MeV and 250 MeV for each 
phantom material 
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The largest percent difference between the stopping powers at the two proton energies 
was less than 1.8%. This agreement indicates that the potential phantom materials can be 
used as anatomical substitutes for proton beam energies between 160 MeV and 250 MeV, as 
the stopping power does not vary with energy significantly. The RSP and percent difference at 
160 MeV was incalculable for concrete. The thickness of the sample in this beam path was 
9cm. The proton beam at this energy was unable to fully penetrate the slab and acquire an 
accurate depth dose curve.  
In order to be considered patient-equivalent in a proton beam for this study, the HU 
needed to fall within the range measured in actual pediatric patients. Additionally, the error 
between the measured RSP and the calculated RSP from Eclipse should be minimal (within 
5%), as this introduces range uncertainties [27]. Based on the measured data in Table 3.1, 
Techron HPV Bearing Grade (Boedeker Plastics, Inc., Shiner, TX) was selected as the bone 
substitute material for the phantom, with a measured HU and RSP of 596 and 1.3, respectively. 
Previous IROC Houston experiments contained data for two materials that closely simulated 
the patient characteristics of cartilage: blue water and PRESAGE®. The error in the proton 
range was calculated to determine the appropriate candidate for the cartilage substitute. This 
calculation was also completed for the Techron HPV Bearing Grade and for Gammex B200, 
another potential bone substitute whose (HU, RSP) point was also in the close proximity to the 
calibration curve. 
To determine the range error, a linear equation was formulated between 2 points on the 
calibration curve surrounding the material point. The measured HU of the material was used to 
determine the ideal RSP that corresponded to the material point lying directly on the curve. A 
percent error was calculated between the measured and calculated RSP. This error was 
translated into mm based on the material thickness when used in the phantom.  An example of 
the linear equation formulation is shown in Figure 3.1. The results of this error calculation for 
the selected phantom materials are shown in Table 3.2. 
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Figure 3.1 Formulation of Linear Equation between 2 (blue) points on HU-RSP 
Calibration curve surrounding a material point (highlighted). The equation is 
represented by the orange line. 
 
Material Name Theoretical 
RSP at 160 
MeV 
Measured 
RSP at 
160 MeV 
Percent 
Error (%) 
Material 
Thickness in 
Phantom(cm) 
Error 
(mm) 
PRESAGE® 1.1 1.1 0.04 2 0.0 
Blue Water 1.1 1.1 0.3 2 0.1 
Techron HPV Bearing 
Grade 1.3 1.3 1.2 4.5 0.6 
Solid Water 1.0 1.0 0.6 11 0.6 
B200 1.1 1.1 5.1 4.5 2.3 
 
Table 3.2 Comparison between measured RSP measurements for phantom tested at 160 
MeV to the RPS calculated by Eclipse for a given HU. 
 
PRESAGE® was not determined to be a feasible cartilage substitute for the phantom. It 
would have been difficult to ensure that the batch used in the phantom would have an identical 
composition to the sample tested in Table 3.2. Therefore, blue water, which was determined to 
have an HU of 86 and a RSP of 1.1, was chosen as the cartilage material. An error of 5.1% 
was observed between the measured and calculated RSP for B200. Although this error only 
translates to a 2mm range uncertainty, the HU of B200 also falls slightly outside the range 
observed in patients. The sub-mm range error and appropriate HU value observed with 
Techron HPV Bearing Grade made this material be the most suitable as the proton bone 
substitute.  
44 
 
Figure 3.2 shows the Eclipse TPS HU-RSP stopping power curve with the data for each 
bone equivalent material tested. The standard deviation of the HU is shown in Figure 3.2 as 
horizontal error bars and the RSP uncertainty at 160 MeV is shown as the vertical error bars for 
each material tested. For the concrete sample data point, the RSP uncertainty at 250 MeV was 
used. The bone material selected shows good accuracy and precision compared to the 
materials that were deemed inadequate for use as proton bone substitutes in the phantom. The 
Techron HPV Bearing Grade material has a 2.3% and 1.9% uncertainty for the measured HU 
and RSP, respectively.  
 
Figure 3.2: Relative Stopping Power vs Hounsfield unit calibration curve comparing 
tested materials with the Eclipse treatment planning system. 
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3.1.2 RSP Error Analysis 
The uncertainty in the measured RSP for each material was computed using Equation 
2.2 for both proton energies. The results are listed in Table 3.3. The percent uncertainty was 
ranged from 1.8-2.0% for all materials tested and the uncertainty for Techron HPV Bearing 
Grade was 1.9%. As previously mentioned, the largest percent difference between the stopping 
powers at 160 and 250 MeV energies was less than 1.8%.This variation was less than the 
uncertainty in the measurement of Techron HPV Bearing Grade. 
 
Material Name % Uncertainty 
at 160 MeV 
% Uncertainty 
at 250 MeV 
Gammex Inner Bone 2.0 2.0 
Gammex Cortical Bone 2.0 2.0 
B200 Bone 2.0 2.0 
Techron HPV Bearing Grade 1.9 1.9 
Ketron PEEK GF30 2.0 1.9 
Polyester PETP Ertalyte TX 1.8 1.8 
Ketron HPV Bearing Grade 1.9 1.9 
Polyester PETP Ertalyte 1.9 1.9 
Duratron T4301 PAI 2.0 2.0 
Concrete N/A 1.1 
Crayola Clay 1.8 1.9 
Table 3.3: Percent Uncertainty in Relative Stopping Power Measurements at 160 MeV 
and 250 MeV 
 
 
3.2  Phantom Design 
The results from the patient measurements acquired from the Eclipse TPS are shown in 
Table 3.4. This information was used to design the internal dimensions of the phantom. A 
portion of this data was also used for determining the HU range when analyzing potential 
phantom materials.  
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Parameter Measurement  
Vertebral body thickness (sagittal cut) 1.25 cm 
Cartilage Thickness  0.25 cm 
Vertebral length 4.5 cm 
Distance from skin to end of vertebral body 6.2 cm 
Distance from Spinous Process to transverse process -Left 1.75 cm 
Distance from Spinous Process to transverse process -Right 1.85 cm 
Diameter of vertebral foramen  1.4 cm  
Skeleton Hounsfield Unit Range 300-1000 HU 
Spinal Cord Hounsfield Unit Range 30-70 HU 
Cartilage Hounsfield Unit Range 80-140 HU 
     
Table 3.4: Summary of anatomical parameters averaged from five craniospinal patients 
  
Figure 3.3 shows the sagittal diagrams of the patient right and left pieces of the phantom 
design. Figure 3.4 is an actual image of these pieces post construction. In the diagram, the 
maroon color represents the soft tissue substitute, while the lighter blue represents the 
cartilage substitute and the dark blue represents the bone substitute. The red holes are the 
TLD in the right superior and left inferior positions. The concentric rectangular pattern 
represents an indentation of 0.25mm, or the thickness of the GAFCHROMIC® film. This 
indentation is more clearly seen in the physical image of the phantom and ensures a sealed 
closure when the sagittal film is placed. What is not visible in the diagram, but visible in Figure 
3.4 are the pen pricks in anterior superior, anterior inferior and posterior inferior positions.  
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Figure 3.3: Sagittal Diagram of the Phantom showing the TLD (red), soft tissue (maroon), 
bone (dark blue) and cartilage (light blue) substitute dimensions. 
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Figure 3.4: Patient Right and Left Pieces of the Phantom  
 
Figure 3.5a shows the coronal diagram of the phantom, representative of the posterior portion 
of the phantom. This piece only contains the transverse process of each vertebra and also has 
a varying thickness to simulate patient spinal curvature. Figure 3.5b shows an actual image of 
this piece and displays the pen pricks in the right superior, left superior and right inferior 
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positions. Figure 3.6 highlights the diagram and image of the posterior wedged piece of the 
phantom with corresponding maximum dimensions. 
 
 
                         
Figure 3.5 Coronal a) Diagram and b) Photo of the Phantom showing the soft tissue 
(maroon) and bone (dark blue) substitute dimensions. 
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a)  
b)  
Figure 3.6: Posterior Wedged Piece a) Diagram with Dimensions and b) Photograph 
3.3  Film Calibration 
The film calibration curve is shown in Figure 3.7.  
 
Figure 3.7 Film Calibration Curve for Batch #07301301 
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The equation used for the optical density to dose conversion in CERR is: 
𝑫𝒐𝒔𝒆 = 𝟐𝟑. 𝟎𝟑𝟔 (𝑶𝑫)𝟑 − 𝟐. 𝟔𝟏𝟗𝟔 (𝑶𝑫)𝟐  + 𝟒. 𝟔𝟏𝟔𝟖 (𝑶𝑫)              Equation 3.1 
The optical density used to determine the points on the curve was an average of three 
measurements. The largest standard deviation observed between OD measurements was 
approximately 1.2%. 
3.4  Passive Scattering Dosimetric Analysis 
3.4.1 Absolute Dose 
The measured TLD dose was compared to the dose calculated by Eclipse. The 
calculated dose to each TLD location was determined based on the mean dose to a contour of 
the TLD capsule in the TPS and used for all absolute dose calculations. The expected dose to 
the right superior TLD and left inferior TLD was 610.2 cGy CGE and 617.9 cGy CGE, 
respectively. The values for the measured and calculated absolute doses, along with the ratio 
between the two dose values are listed in Table 3.4. 
Passive Scatter TLD Absolute Dose Results 
Irradiation 
Trial # 
TLD Location Calculated TPS 
Dose (cGy-RBE) 
Measured TLD 
Dose (cGy-RBE) 
Measured/ 
Calculated 
1 Right Superior 610.2 616.0 1.009 
1 Left Inferior 617.9 628.4 1.017 
2 Right Superior 610.2 612.9 1.004 
2 Left Inferior 617.9 625.2 1.012 
3 Right Superior 610.2 618.9 1.014 
3 Left Inferior 617.9 629.4 1.019 
Table 3.5 Passive Scatter Irradiation Absolute Dose Results 
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The evaluation criterion for the TLD point dose was that the measured dose should be within 
±5% of the expected dose. The measured TLD results were all within 2%, successfully passing 
this evaluation segment.  
The coefficient of variation was calculated as a part of a reproducibility study. Three 
irradiations of the same plan and setup were conducted to determine whether this phantom 
experiment could be easily recreated. The measured physical dose from this was averaged 
over 3 trials and the mean divided by the standard deviation of these measurements was 
compared to the tolerance value. The reproducibility results were less than 0.5%, passing the 
3% tolerance criterion. This suggests that if institutions correctly setup the phantom per IROC 
Houston instructions, the irradiations should produce similar results.  
Coefficient of Variation Calculations 
TLD Location Right Superior Left Inferior 
 
Average TPS Calculated RBE 
Dose 
610.2 617.9 
Average Measured RBE  
Dose 
615.9 627.7 
Measured/Calculated Ratio 1.009 1.02 
Standard Deviation 3.0 2.2 
COV (%) 0.5 0.4 
Table 3.6 Passive Scatter Irradiation Reproducibility Study Results 
3.4.2  2D Gamma Analysis 
The dose distributions from the film and the treatment planning system were compared 
for analysis after the 2D and 3D registrations were complete. The 2D RMS error for the film 
was in the range of 0.5-1.0 mm, while the 3D RMS error was in a range of 1.3-1.6 mm. A 2D 
gamma analysis was formed on each trial data set. The hypothesis used a passing criterion of 
±5%/3mm. Additionally, a second analysis was performed using a ±5%/5mm for comparison. 
An example of the gamma analysis color map produced by CERR is shown in Figure 3.8. A 
blue or green pixel returns a gamma value less than 1 and is considered a passing pixel. 
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Yellow, orange and red pixels return gamma values greater than 1, which is considered not 
meeting the criteria. The results from the 2D gamma analysis for the passive scatter 
irradiations are listed in Table 3.7. 
a)  b)  
Figure 3.8 2D Gamma Analysis Color Maps from Passive Scattering Trial 2 data in 
the a) coronal and b) sagittal planes for the 5%/5mm criteria 
 
5%/5mm Passing Criteria 5%/3mm Passing Criteria 
Trial Coronal Sagittal Trial Coronal Sagittal 
1 99% 81% 1 96% 67% 
2 99% 95% 2 99% 85% 
3 99% 94% 3 95% 90% 
Table 3.7 2D Gamma Analysis Passing Rates for Passive Scattering Trials 
 Following the stated passing pixel rate in the hypothesis of 85%, each coronal plane 
passed the 5%/5mm and the 5%/3mm criteria. Trials 2 and 3 in the sagittal plane also passed 
both criteria successfully. Trial 1 in the sagittal plane failed both criteria. It is expected that the 
5%/5mm criteria would show a higher pass rate compared to the stricter criteria, as this allows 
for more disparity between the compared distributions; this was observed. For both sets of 
criteria, the coronal plan had better passing rates compared to the sagittal plane. This could be 
due to this film being placed parallel to the beam axis, making it a harder plane to pass as the 
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linear energy transfer (LET) increases in this direction. Additionally, on the sagittal films, there 
was consistent failure seen in the distal fall off region and in the superior and inferior directions 
outside the CTV, possibly due to the increase in LET at the end of the range and scatter from 
the field edges of the aperture, respectively. For the coronal films, most failure is observed in 
the lower spine field in the CTV and on the right film edge. Based on these results, the 
5%/5mm gamma analysis is the more suitable criteria for this phantom. This criteria is partially 
consistent with the criteria used for the current anthropomorphic proton spine phantom at 
IROC-H.  
3.4.3 Profile Analysis 
The dose profiles at various positions were plotted in all three directions of the phantom. 
The coronal film is used for the right-left alignment profiles and for the cold spot peak profile. 
The sagittal film not only verified the range, hot spot location and determined how conformal 
the dose delivered was, but also allowed for observation (through the anterior-posterior profiles 
and DTA measurements) of dose matching at the heterogeneous interfaces. The sagittal plane 
films clearly show the extended proton range at each individual cartilage disk due to the 
change in the stopping power between the three tissue substitutes.  An example of the coronal 
and sagittal films, along with the respective locations of the profiles is shown in Figure 3.9.  
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Figure 3.9: Images of the digitized film in the a) coronal and b) sagittal planes for 
Passive Scattering Trial 3. The black lines represent the locations where dose profiles 
were acquired. 
 
The average data from the distance to agreement measurements and percent dose 
differences at the hot/cold spot peaks is shown in Table 3.8. An example of the right-left, 
anterior-posterior, and superior-inferior profiles for Trial 3 are shown in Figures 3.10-3.15. For 
the field displayed in Figure 3.9, more disagreement is displayed on the left gradient region. In 
Figure 3.10, more disagreement is displayed in the right gradient region. Observed in the 
anterior-posterior film profiles (Figures 3.12 and 3.13) are under-responses in the distal fall off 
region and over-responses past the end of the range. Possible explanations for these 
phenomena will be explored in Section 3.5. 
Film Plane 
Avg. Distance to 
Agreement  
SD 
(mm/%) Criteria 
Coronal R/L Agreement-Sup.  2.1 mm 0.2 5mm 
Coronal R/L Agreement-Inf. 1.0 mm 0.3 5mm 
Sagittal A/P Agreement-Sup. 1.3 mm 0.8 5mm 
Sagittal A/P Agreement-Inf. 1.0 mm 0.3 5mm 
Coronal S/I Junction Shift 1.8 mm 1.7 5mm 
Sagittal S/I Junction Shift 3.0 mm 0.3 5mm 
% Dose Difference-Coronal 2.0% 1.5 7% 
% Dose Difference-Sagittal 1.2% 0.9 7% 
Table 3.8 Passive Scattering Trials Average Distance to Agreement Results 
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Figure 3.10 R-L Dose Profile for the passive scattering trial 3 upper spine field,  
measured in the coronal Plane 
 
 
Figure 3.11 R-L Dose Profile for the passive scattering trial 3 lower spine field, 
measured in the coronal Plane 
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Figure 3.12 A-P Dose Profile for the passive scattering trial 3 upper spine field,  
measured in the Sagittal Plane 
 
 
Figure 3.13 A-P Dose Profile for the passive scattering trial 3 lower spine field,  
measured in the sagittal Plane 
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Figure 3.14 S-I Dose Profile for the passive scattering trial 3 measured in the coronal 
Plane 
 
 
Figure 3.15: S-I Dose Profile for the passive scattering trial 3 measured in the sagittal 
Plane 
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Based on the average data presented above, the phantom passed all criteria for the 
experimental evaluation. Individually, all profiles acquired in the coronal and sagittal planes 
passed criteria.  The remaining profiles acquired from the coronal and sagittal planes are 
shown in the appendix.  
The standard deviations for the junction shift DTA measurements are largest, with a 
maximum over 3mm. All other deviations are between approximately 1-2mm, suggesting that 
the DTA trends were consistent over all profiles.  
 
 
3.5  Spot Scanning Dosimetric Analysis 
3.4.1  Absolute Dose 
The dose measured in the TLD irradiated using a spot scanning beam was compared to 
the TLD dose calculated by Eclipse. The calculated dose to each TLD was averaged in the 
same manner as the passive scatter irradiations. The expected dose to the right superior TLD 
and left inferior TLD was 611.4 cGy CGE and 604.6 cGy CGE, respectively. The values for the 
measured and calculated absolute doses, along with the ratio between the set of 
measurements is listed in Table 3.9. 
Spot Scanning TLD Absolute Dose Results 
Irradiation 
Trial # 
TLD Location Calculated TPS 
Dose (cGy CGE) 
Measured TLD 
Dose (cGy-CGE) 
Measured/ 
Calculated 
1 Right Superior   617.4 629.2 1.019 
1 Left Inferior 617.3 577.5 0.935 
2 Right Superior 617.4 628.5 1.017 
2 Left Inferior 617.3 574 0.929 
3 Right Superior 617.4 628.5 1.017 
3 Left Inferior 617.3 577.1 0.934 
Table 3.9 Spot Scanning Irradiation Absolute Dose Results 
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The evaluation criterion for the TLD point dose was that the measured dose should be within 
±5% of the expected dose. The measured right superior TLD results were consistently higher 
than the planned doses and all results are within 3%, successfully passing. The measured left 
inferior TLD results were lower than the planned doses and did not pass criteria.  
The coefficient of variation results for the spot scanning irradiations are listed in Table 
3.10. The reproducibility results were less than 0.5%, suggesting that correct setup of the 
phantom will yield accurate results, regardless of the beam delivery technique.  
Coefficient of Variation Calculations 
TLD Location Right Superior Left Inferior 
 
TPS Calculated RBE Dose 617.4 617.3 
 
Measured RBE  Dose 
628.4 575.9 
Measured/Calculated Ratio 
1.018 0.933 
Standard Deviation 0.4 1.9 
COV (%) 
0.1 0.3 
Table 3.10 Spot Scanning Irradiation Reproducibility Study Results 
3.5.2  2D Gamma Analysis 
The spot scanning dose distributions from the film and TPS were compared for 
analysis. The 2D RMS error for the film was in a range of 0.5-1.0mm, while the 3D RMS error 
was in a range of 1.3-1.4 mm.  The gamma analysis was performed for the passing criteria of 
5%/5mm and 5%/3mm. The spot scanning gamma analysis color map with criteria of 5%/5mm 
is shown in Figure 3.16. The results from the 2D gamma analysis for the spot scanning 
irradiations are listed in Table 3.11. 
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a) b)  
Figure 3.16 2D Gamma Analysis Color Maps from Spot Scanning Trial 1 data in 
the a) coronal and b) sagittal planes for 5%/5mm criteria 
 
5%/5mm Passing Criteria 5%/3mm Passing Criteria 
Trial Coronal Sagittal Trial Coronal Sagittal 
1 91% 82% 1 86% 72% 
2 91% 82% 2 88% 73% 
3 91% 84% 3 79% 77% 
Table 3.11 2D Gamma Analysis Passing Rates for Spot Scanning Trials 
Following the stated passing pixel rate in the hypothesis of 85%, only the coronal plane 
had all three trials meet this objective for the 5%/5mm criteria. Trial 3 of the coronal planes 
failed the 5%/3mm criteria. None of the six gamma analyses calculated in the sagittal plane 
passed for either criteria. Failure is observed in the middle of the CTV for all the spot scanning 
gamma color maps. Additionally, the same failure at the end of the range observed during the 
scattered beam analyzes is observed for spot scanning. As seen in the passive scattering 
irradiations, the 5%/5mm criteria showed a higher pass rate as expected. For both sets of 
criteria, the coronal plan had better passing rates compared to the sagittal plane.  
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3.5.3 Profile Analysis 
The dose profiles were plotted in all directions of the phantom and most were acquired 
approximately in the same locations as those for the passive scattering irradiations. The 
superior-inferior profile on the sagittal plane was moved slightly away from the edge of the 
range. An example of the coronal and sagittal films, along with the respective locations of the 
profiles is shown in Figure 3.17. 
a)  
b)  
Figure 3.17 Images of the digitized film in the a) coronal and b) sagittal planes for Spot 
Scanning Trial 3. The black lines represent the locations where dose profiles were 
acquired. 
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The average DTA measurements are shown in Table 3.12. Figures 3.18-3.22 shows the 
profiles acquired for trial 3, which had an average performance over all measurements. Figures 
3.18 and 3.19 display a more gradual fall off in the high dose region compared to the scattered 
beam profiles. Also, there is more disagreement on the right side compared to the left side for 
both profiles. Figure 3.20 not only displays a similar under response in the distal fall off region 
and over response past the target volume for the film profile, but also displays a large under 
response in the SOBP region. Each profile acquired through the cartilage substitute exhibited 
this discrepancy (see Appendix), with up to a 10% response lower compared to the TPS. This 
effect was not as prominent for A-P profiles acquired through the bone. All profiles passed the 
DTA criteria, but the spot scanning plan junction could not be evaluated in the same manner as 
the passive scattering plan junction. 
 
Film Plane 
Avg. Distance to 
Agreement (mm) SD (mm) Criteria 
Coronal R/L Agreement-Superior Field 2.0 0.7 5mm 
Coronal R/L Agreement- Inferior Field 2.4 0.7 5mm 
Sagittal A/P Agreement-Superior Field 0.4 0.3 5mm 
Sagittal A/P Agreement-Inferior Field 0.7 0.2 5mm 
Coronal S/I Junction Shift N/A N/A 5mm 
Sagittal S/I Junction Shift N/A N/A 5mm 
% Dose Difference-Coronal N/A N/A 7% 
% Dose Difference-Sagittal N/A N/A 7% 
 
Table 3.12 Spot Scanning Trials Average Distance to Agreement Results 
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Figure 3.18 R-L Dose Profile for the Spot scanning trial 3 upper spine field, measured in 
the coronal Plane 
 
Figure 3.19 R-L Dose Profile for the Spot scanning trial 3 lower spine field, measured in 
the coronal Plane 
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Figure 3.20 A-P Dose Profile for the Spot scanning trial 3 lower spine field, measured in 
the Sagittal Plane 
Quantitative evaluation of the junction shift was unable to be determined. Spot scanning 
junctions do not have gaps at the patient surfaces and matches a certain depth like traditional 
junctions, so the TPS profile data doesn’t show a comparison peak. Additionally, the substantial 
variation in the film dose distribution does not reveal any defined peaks, further increasing the 
difficulty for junction analysis. The variations in the film profile explain the gamma analysis 
failure regions on the sagittal film, especially in the inferior direction (See Figure 3.21). This 
clearly shows a discrepancy in the predicted dose by the planning system and the measured 
dose.  
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Figure 3.21 S-I Dose Profile for the Spot scanning trial 3, measured in the coronal Plane 
 
Figure 3.22 S-I Dose Profile for the Spot scanning trial 3, measured in the sagittal Plane 
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Based on the average data presented above, the phantom quantitatively passes all 
DTA criteria for the experimental evaluation, despite the qualitative issues observed.  The 
standard deviations are less than 1mm, suggesting that the DTA trends were similar over all 
profiles.  
 
3.6  Beam Delivery Dosimetric Analysis Comparison 
Quantitatively, the DTA results from the passive scattering and spot scanning 
irradiations are comparable. However, it is very apparent that the passive scattering irradiations 
produced better results. Two of the 12 total gamma calculations conducted from the passive 
scattering irradiations failed, while 7 of the 12 calculated failed for the spot scanning 
measurements. The measured/calculated TLD ratios for passive scattering were all within 2%. 
The ratios for the right superior TLD from the spot scanning technique did pass the 5% 
tolerance, but the results for the left inferior TLD did not. The average distance to agreement in 
the right, left, anterior and posterior directions was comparable between both beam delivery 
techniques. Overall, the DTA was less than 3mm in these directions with a standard deviation 
of less than 1mm for all measurements. As previously mentioned, the junction was not able to 
be quantitatively evaluated from the spot scanning irradiations. Therefore, no dosimetric 
comparison between the techniques can be completed. A summary of the all phantom 
evaluation results is listed in Table 3.13. 
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 Passive Scattering Spot Scanning 
 Average Worst Average Worst 
Right Superior TLD 1.009 1.014 1.028 1.029 
Left Inferior TLD 1.016 1.019 0.932 0.929 
5%/5mm Gamma Analysis 95% 81% 87% 82% 
5%/3mm Gamma Analysis 89% 67% 79% 72% 
Right/Left DTA (mm) 2.1/1.0 2.3/1.0 2.0/2.4 2.7/1.3 
Anterior/Posterior DTA (mm) 1.3/1.0 2/1.1 0.4/0.7 0.6/1.0 
Coronal/Sagittal Junction Shift 1.8/3.0 3.3/3.3 N/A N/A 
% Dose Difference-Coronal 2.0 3.6 N/A N/A 
% Dose Difference-Sagittal 1.2 1.8 N/A N/A 
Table 3.13 Comprehensive Summary of Phantom Experiment Results 
Two characteristics seen in the right, left, anterior and posterior profiles were the under-
estimation of dose in the SOBP and the over-estimation of the tail energy.  An example of 
these effects is shown in Figure 3.23.  
 
Figure 3.22: A-P Spot Scanning Dose Profile for upper spine field in Trial 3, highlighting 
the under response in the SOBP and the over response in the low dose region 
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These responses were seen for both delivery techniques, possibly due to the film’s 
sensitivity to high LET radiation [42]. With the increase in the LET in the SOBP at the end of the 
range, a quenching effect occurs. Darkening of the film saturates and the increase in LET does 
not lead to an increase in the dose response. This under-response in the SOBP ranges 
anywhere from 5-40% in previous studies for a variety of radiochromic films types [43, 44]. 
Additionally, residual energy is observed in the film profiles at the end of the range due to 
secondary neutrons from nuclear interactions. These secondary particles also have a high LET 
that causes variation in the film profiles, leading to dose deposition outside the target [18].  
The passive scattering results deemed it acceptable for send-off to an institution that 
conducts similar beam deliveries. Based on the results, it is best to use the 5%/5mm gamma 
analysis criteria with 85% of pixels passing. The DTA criteria of 5mm in all directions, along 
with no more than a 5mm spatial shift or a 7% dose difference at the junction were shown to be 
suitable criteria for the passive scattering deliveries. Some of these criteria, such as the DTA 
criteria and the percent dose difference at the junction, could be stricter than what was 
evaluated. 
More testing will need to be conducted on the phantom with spot scanning before the 
phantom can be used as an auditing tool for this technique. It has been determined that the 
junction area cannot be evaluated in the same manner as for passive scattering. Therefore, 
new methods and evaluation metrics need to be explored. Because no trial passed the gamma 
analysis for both film planes, the possibility of using a different criteria may also need to be 
explored based on resolution regarding the observed dose variations. 
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3.7  Investigation of Spot Scanning Delivery Results 
With discrepancies more prominently observed for the spot scanning profiles, it was 
suggested that an issue occurred with the treatment planning system calculations or with the 
treatment delivery system. In addition to quenching, the dose past the end of the range and 
problems in the dose calculation algorithms were investigated.  
It was suspected that the dose deposited past the target was due to secondary particles 
that were produced in the phantom from nuclear interactions. Figure 3.24 shows the percent 
absorbed dose due to secondary particles produced [45]. The dose deposited past the end of 
the range is less than 0.1% of the total absorbed dose. This percentage would be higher for 
bone, as it yields the generation of more secondary particles.  The profiles from this study 
showed that the dose deposit outside the target was about 8-10% of the reference dose. So 
although nuclear fragments may contribute to this over response in the tail, its contribution is 
rather small. 
 
Figure 3.24: (from Paganetti et. al) Percent Dose contributions of secondary 
particles for a 160 MeV proton beam 
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Next, the optimization techniques were explored. For multi field optimization, the spots 
used to create the dose from the 2 fields were simultaneously optimized. Due to differences in 
the spot intensities, the dose distribution per beam can be very inhomogeneous. And because 
there are no smearing margins to account for misalignment like with scattered deliveries, the 
range and setup uncertainties can have a large effect on the dose that is actually delivered.  
This effect has been shown in patient cases. Figure 3.25 shows dose distributions 
comparing the PTV-Based, or non-robust optimized plan, to the robustly optimized plan [46] for 
a head and neck case. The top row shows the distributions without any uncertainties accounted 
for in the planning. The bottom row shows how the dose distributions will appear the patient 
setup was off by 3mm. Comparing the non-robust plans, the bottom image has a very 
inhomogeneous dose due to the introduced shift in the patient. The robust plans have some 
changes between the 2 distributions, but there is still adequate target coverage. This possibly 
relates to the dose variation seen in the spot scanning profiles. But there may be inaccuracies 
in the dose calculation in the presence of inhomogeneous media which may also have an effect 
on the results. 
 
Figure 3.25: (from Liu et. al) Comparison of non-robustly optimized and robustly 
optimized plans in a head and neck case 
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The Eclipse treatment planning system uses the same pencil beam algorithm for both 
passive scattering and spot scanning treatment plans, with the difference occurring in the in-air 
fluence modeling [47]. Studies have reported that inaccuracies in the dose calculations may 
occur when an inhomogeneous media is placed in the beam [47, 48]. Figures 3.26a and 3.26b 
from Yamashita et. al compared pencil beam dose calculations to Monte Carlo calculations. 
Monte Carlo algorithms are considered the most accurate algorithms to compute dose.  
a)  
b)  
Figures 3.26 (from Yamashita et. al) Comparison of the dose distributions 
calculated from Pencil Beam and Monte Carlo algorithms with a) measurements 
in a water phantom and b) the gamma index between both algorithms in the 
proton range axis 
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Shown in Figure 3.26a are measurements taken in a water phantom along the range 
direction compared to the dose calculated by a pencil beam algorithm and by Monte Carlo 
algorithm. Although all three plots relatively agree, there is some discrepancy between them in 
the distal fall off region. The measurements tend to have better agreement with the Monte 
Carlo calculation. Figure 3.26b shows the dose profile calculated between the planning system 
and Monte Carlo in the range direction, along with a gamma analysis comparing the two 
distributions. The same disagreement is shown in the distal fall off, but there is also 
disagreement in the tail. This difference is confirmed by the increase in the gamma values at 
these locations. The observed correlations in Yamashita et. al differ slightly from the 
observations in the profiles from this study, as this is a different planning system (XiO). 
However, the conclusion is there are inaccuracies in the dose calculation that may be the main 
reason for the mismatch between the TPS measured profiles and the film profiles. 
For the phantom films, the response was up to 10% lower than the predicted TPS 
calculation in the SOBP, and up to 15% lower in the distal fall off region. To determine why 
such magnitude of variation was observed, especially with the use of a junction and multi-field 
optimization method, an additional single field spot scanning irradiation was performed. Plan 
parameters and energy were comparable to the scanning plan using the 2 field geometry. This 
plan was delivered and the dosimeters were evaluated in the same manner as for the 2-field 
spot scanning treatment plan.  
The TLD results from the single field scanning delivery are shown in Table 3.14. The 
measured TLD dose was consistently lower than the calculated dose for both the left inferior 
and right superior TLD. Similar to the previous spot scanning results, the left inferior measured 
TLD dose was lower than its counterpart. Both TLD were within passing criteria. 
 
74 
 
T LD Location Right Superior Left Inferior 
Measured Dose 595.6 583.9 
Calculated-TPS Dose 610.1 617.9 
Ratio (Measured/Calculated) 0.976 0.950 
Table 3.14: Single Field Spot Scanning Irradiation TLD Results 
The 2D gamma analysis was again calculated for both film planes using criteria of 
5%/5mm and 5%/3mm. The gamma color maps from the coronal plane (Figure 3.27) display 
failure in the CTV that was observed in similar locations in the previous spot scanning gamma 
analysis. The coronal plane passes the 5%/5mm criteria, while failing the 5%/3mm criteria. The 
sagittal plane does not pass either criterion. Using the less strict criteria, there is some 
disagreement observed in the CTV with prominent failure at the end of the distal range. The 
disagreements are magnified as the criterion is tightened.  
Film Plane Coronal Sagittal 
5%/5mm Passing 
Percentage 
88% 54% 
5%/3mm Passing 
Percentage 
84% 33% 
Table 3.15: 2D Gamma Analysis Results for Single Field Spot Scanning Trial 
a) b)  
Figure 3.27: 2D Gamma Color Maps from Single Field Spot Scanning Delivery in 
the coronal plane using a) 5%/5mm and b)5%/3mm criteria 
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a) b)  
Figure 3.28: 2D Gamma Color Maps from Single Field Spot Scanning Delivery in 
the sagittal plane using a) 5%/5mm and b) 5%/3mm 
 
Examining the treatment plan closely, a view of the left inferior TLD in the axial plane is 
shown in Figure 3.29. This view shows a hot spot in the middle of the CTV. A hot spot in this 
location would not be as sharp and prominent on a passive scattering plan, as the dose should 
scatter out of the plane. This suggests that the passive scattering deliveries are less sensitive 
to deficiencies in the algorithm compared to the spot scanning deliveries, due to the small 
differences in the dose calculation models between the two techniques. 
 
Figure 3.29 Axial View of the Left Inferior TLD in the Single Field Spot Scanning 
Treatment Plan 
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The right-left profile acquired in the superior and inferior field is shown in Figures 3.30 
and 3.31, respectively. More disagreement between the TPS and film is observed on the right, 
consistent with the results seen from previous spot scanning irradiations. However, there is 
now an under response in the dose spanning the target (5-6%). A reason for this effect is due 
to the film normalization to TLD that were consistently lower than the dose calculated by the 
treatment plan. 
 
Figure 3.30: Right-left profile in the superior field for single field spot scanning trial, 
measured in the coronal plane 
77 
 
 
Figure 3.31: Right-left profile in the inferior field for single field spot scanning trial, 
measured in the coronal plane 
 
Displayed in Figures 3.32 and 3.33 are the A-P profiles acquired through the bone and 
through the cartilage. An under-response of the film in still observed in the SOBP and distal fall 
off regions (7-8% in both profiles), along with an over-response past the end of the proton 
beam range (up to 1 Gy on bone profile, >1 Gy for cartilage profile). The profiles for bone are 
cartilage appear to display similar responses compared to the large differences observed 
between these two profiles in the previous scanning beam analysis.  
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Figure 3.32: A-P Profile in the superior field through bone for Single field spot scanning 
trial, measured in the sagittal plane 
 
Figure 3.33: A-P Profile in the Inferior field through cartilage for Single Field Spot 
Scanning Trial, measured in the sagittal plane 
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Figures 3.34 and 3.35 show the superior-inferior profiles in the coronal and sagittal 
planes. The dose variation observed in the film is comparable to the dose from the treatment 
planning system, suggesting that the overlapping junction region may have contributed to the 
significant dose variation. Similar to the right-left profiles, there is an under dosing of the target 
(7% in the coronal plane, 10% in the sagittal plane). 
 
Figure 3.34: S-I Profile for Single Field Spot Scanning trial, measured in the coronal 
plane
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Figure 3.35: S-I Profile for Single Field Spot Scanning trial, measured in the sagittal 
plane 
 
Although some differences between the dose profiles of the single field and multiple 
field scanning deliveries are observed, overall, the results are quite similar. The results from the 
single field spot scanning irradiation further suggests that problems with the scanning dose 
calculation algorithms and corrections to quenching in the film dosimeter should be 
investigated.  
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4  Conclusions 
4.1  Meeting Specific Aims 
The purpose of this study was to design an anthropomorphic pediatric spine phantom 
for use in the evaluation of proton therapy facilities for clinical trial participation by IROC 
Houston. The hypothesis states that this phantom can be designed and assures that the 
measured doses would agree with the calculated doses with a 5%/3mm criteria and a TLD 
point dose agreement within 5%.  
The first specific aim was to design a phantom that accurately simulated a patient in the 
thoracic region of the spinal column. Potential tissue equivalent materials were evaluated by 
determining the HU and RSP and then comparing each to the HU-RSP calibration curve. The 
materials used in the phantom-Techron HPV Bearing Grade, solid water and blue water- are 
within 2% of the HU and RSP in the Eclipse treatment planning system used by the PTC-H. 
The successful determination of tissue equivalency renders this specific aim complete.  
The second specific aim required imaging of the phantom and creating clinically 
relevant treatment plans for both irradiation techniques. The phantom was CT-scanned at the 
PTC-H, and these images were used to create both a passive scattering treatment plan and a 
spot scanning treatment plan. With the assistance of a proton dosimetrist, these plans were 
adjusted to a clinically acceptable level that met dose constraints outlined by a radiation 
oncologist. The phantom was then irradiated a total of 6 times at our institution, completing the 
second aim.  
The third specific aim was to measure the dose distributions from the treatment 
deliveries using radiochromic film and TLD. Two pieces of film, one in the coronal plane and 
one in the sagittal plane, were used per delivery to measure the planar distributions. The batch 
of film was calibrated to ensure that the dose conversion was accurate. Two TL dosimeters, in 
the right superior and left inferior locations of the spinal canal, were used to measure the 
absolute dose. Relevant information from the batch previously characterized was used to 
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determine the measured point dose. The calibration of the film and TLD along with the proper 
placement of these dosimeters in the phantom completes the third aim.  
The fourth specific aim required analysis of the dose distribution data to determine the 
accuracy of all work done in specific aims 1, 2, and 3. During the dose profile comparison of the 
data between the film, TLD, and TPS, the following attributes were evaluated: absolute dose 
agreement, distal range, field width, junction match and right/left profile alignment. The average 
pixel pass rate for gamma analysis of the passive scatter irradiations was 94.7% for the 
5%/5mm criteria and 88.8% for the 5%/3mm criteria. The average pixel pass rate for gamma 
analysis of the spot scanning irradiations was 86.8% for the 5%/5mm criteria and 79.4% for the 
5%/3mm criteria. The determination of the dose differences and agreement completes the last 
specific aim of the project. 
There were some limitations seen in this study. For the passive scattering irradiation, a 
sum plan of 2 junction plans was delivered to the phantom. Because this approach includes 
feathering at the junction, the dose distribution from the hot and cold spots was smoothed out. 
While this technique reflected current clinical practice, it made evaluation of a single dose 
match point more difficult. The feathered junction approach was not used for the spot scanning 
plans. Due to differences at the junction region between the two delivery techniques, the spot 
scanning junction profiles were unable to be evaluated.  
 
4.2  Clinical Significance 
Developing a phantom that audits the accuracy of simulation, dose calculation from the 
treatment planning system and the treatment delivery of proton therapy is becoming 
increasingly more important. With the opening of more proton therapy centers, it is imperative 
that IROC Houston update their quality assurance tools used to credential institutions for 
clinical trial participation. Although IROC Houston currently has two commissioned phantoms 
for proton therapy, the deterioration of the spine phantom called for the development of a new 
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remote auditing tool. The spine phantom developed for this study proves suitable for use during 
the baseline proton approval process in the same manner as the phantom that contains human 
vertebrae. Institutions will still be required by IROC Houston to follow NCI approval guidelines 
and to complete a full audit before patients can be treated on protocol. Completion of the 
approval and credentialing process ensures that clinically comparable doses can be safely 
delivered to a patient and also that accurate, trustworthy clinical trial results can be obtained.  
 
4.3  Future Directions 
The outcome of this study shows that the phantom is ready for use as a quality 
assurance tool for passive scatter proton beams. The spot scanning irradiations should be 
repeated and better pass rates for all criteria should be achieved. More institutions will need to 
complete preliminary audits to verify our results and the feasibility of use. The phantom design 
can be adjusted by adding critical structures to the phantom to not only further increase the 
difficulty threshold of passing, but also to verify the proton range and the dose to the critical 
structures.  
The procedure for irradiation currently only calls for imaging using CT. However, 
radiation oncologists at PTC-H may contour patient anatomical structures on MRI-fused 
images. Materials that comprise most anthropomorphic phantoms are not always 
distinguishable on MRI images, causing difficulty when determining the imaging procedure for 
this phantom. Future work includes using magnetic resonance imaging (MRI) for normal 
structure and lesion delineation and fused with a CT image to complete the dose calculations. 
Additional future work with this phantom includes a repeat phantom experiment using the spot 
scanning technique, the assessment of robust optimization of IMPT for use in CSI irradiations, 
a comparison with the dose verification of the phantom when setup in the prone position, and 
lastly, the testing of the film and TLD to accurately measure the dose distributions when 
irradiating with the oblique angles used in CSI treatments.  
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5  Appendix 
5.1  Gamma Analysis 
5.1.1  Passive Scattering Irradiations 
 
a) 5%/5mm pass rate: 99.57%                    b) 5%/3mm pass rate: 96.43% 
Figure 5.1 Passive Scattering Trial 1 Irradiation 2D Coronal Gamma Analysis 
 
 
a) 5%/5mm pass rate: 81.23%                    b) 5%/3mm pass rate: 67.44% 
Figure 5.2 Passive Scattering Trial 1 Irradiation 2D Sagittal Gamma Analysis 
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a) 5%/5mm pass rate: 99.21%                    b) 5%/3mm pass rate: 98.91% 
Figure 5.3 Passive Scattering Trial 2 Irradiation 2D Coronal Gamma Analysis 
 
 
 
 
a) 5%/5mm pass rate: 94.57%                    b) 5%/3mm pass rate: 84.68% 
Figure 5.4 Passive Scattering Trial 2 Irradiation 2D Sagittal Gamma Analysis 
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a) 5%/5mm pass rate: 99.36%                    b) 5%/3mm pass rate: 95.13% 
Figure 5.5 Passive Scattering Trial 3 Irradiation 2D Coronal Gamma Analysis 
 
 
  
a) 5%/5mm pass rate: 94.13%                    b) 5%/3mm pass rate: 90.01% 
Figure 5.6 Passive Scattering Trial 3 Irradiation 2D Sagittal Gamma Analysis 
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5.1.2  Spot Scanning Irradiations 
  
a) 5%/5mm pass rate: 90.87%                    b) 5%/3mm pass rate: 86.28% 
Figure 5.7 Spot Scanning Trial 1 Irradiation 2D Coronal Gamma Analysis 
 
  
a) 5%/5mm pass rate: 81.94%                    b) 5%/3mm pass rate: 71.51% 
Figure 5.8 Spot Scanning Trial 1 Irradiation 2D Sagittal Gamma Analysis 
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a) 5%/5mm pass rate: 90.57%                    b) 5%/3mm pass rate: 88.25% 
Figure 5.9 Spot Scanning Trial 2 Irradiation 2D Coronal Gamma Analysis 
 
    
a) 5%/5mm pass rate: 82.42%                    b) 5%/3mm pass rate: 73.34% 
Figure 5.10 Spot Scanning Trial 2 Irradiation 2D Sagittal Gamma Analysis 
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a) 5%/5mm pass rate: 91.00%                    b) 5%/3mm pass rate: 79.42% 
Figure 5.11 Spot Scanning Trial 3 Irradiation 2D Coronal Gamma Analysis 
 
   
a) 5%/5mm pass rate: 84.12%                    b) 5%/3mm pass rate: 77.45% 
Figure 5.12 Spot Scanning Trial 3 Irradiation 2D Sagittal Gamma Analysis 
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5.2  Dose Profiles 
5.2.1  Passive Scattering Trial Comparisons 
 
Figure 5.13 R-L Dose Profile for the passive scattering trial 1 upper spine field, 
measured in the coronal Plane 
 
Figure 5.14 R-L Dose Profile for the passive scattering trial 1 lower spine field, measured 
in the coronal Plane 
91 
 
 
Figure 5.15 A-P Dose Profile for the passive scattering trial 1 upper spine field, 
measured in the Sagittal Plane 
 
Figure 5.16 A-P Dose Profile for the passive scattering trial 1 lower spine field, measured 
in the sagittal Plane 
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Figure 5.17 S-I Dose Profile for the passive scattering trial 1, measured in the coronal 
Plane 
 
Figure 5.18 S-I Dose Profile for the passive scattering trial 1, measured in the sagittal 
Plane 
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Figure 5.19 R-L Dose Profile for the passive scattering trial 2 upper spine field, 
measured in the coronal Plane 
 
Figure 5.20 R-L Dose Profile for the passive scattering trial 2 lower spine field, measured 
in the coronal Plane 
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Figure 5.21 A-P Dose Profile for the passive scattering trial 2 upper spine field, 
measured in the Sagittal Plane 
 
Figure 5.22 A-P Dose Profile for the passive scattering trial 2 lower spine field, measured 
in the sagittal Plane 
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Figure 5.23 S-I Dose Profile for the passive scattering trial 2, measured in the coronal 
Plane 
 
Figure 5.24 S-I Dose Profile for the passive scattering trial 2, measured in the sagittal 
Plane 
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Figure 5.25 R-L Dose Profile for the passive scattering trial 3 upper spine field, 
measured in the coronal Plane 
 
Figure 5.26 R-L Dose Profile for the passive scattering trial 3 lower spine field, measured 
in the coronal Plane 
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Figure 5.27 A-P Dose Profile for the passive scattering trial 3 upper spine field, 
measured in the Sagittal Plane 
 
Figure 5.28 A-P Dose Profile for the passive scattering trial 3 lower spine field, measured 
in the sagittal Plane 
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Figure 5.29 S-I Dose Profile for the passive scattering trial 3, measured in the coronal 
Plane 
 
Figure 5.30 S-I Dose Profile for the passive scattering trial 3, measured in the sagittal 
Plane 
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5.2.2  Spot Scanning Trial Comparisons 
 
Figure 5.31 R-L Dose Profile for the Spot scanning trial 1 upper spine field, measured in 
the coronal Plane 
 
 
Figure 5.32 R-L Dose Profile for the Spot scanning trial 1 lower spine field, measured in 
the coronal Plane 
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Figure 5.33 A-P Dose Profile for the Spot scanning trial 1 upper spine field, measured in 
the Sagittal Plane 
 
 
Figure 5.34 A-P Dose Profile for the Spot scanning trial 1 lower spine field, measured in 
the sagittal Plane 
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Figure 5.35 S-I Dose Profile for the Spot scanning trial 1, measured in the coronal Plane 
 
 
Figure 5.36 S-I Dose Profile for the Spot scanning trial 1, measured in the sagittal Plane 
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Figure 5.37 R-L Dose Profile for the Spot scanning trial 2 upper spine field,  
measured in the coronal Plane 
 
Figure 5.38 R-L Dose Profile for the Spot scanning trial 2 lower spine field,  
measured in the coronal Plane 
103 
 
 
Figure 5.39 A-P Dose Profile for the Spot scanning trial 2 upper spine field,  
measured in the Sagittal Plane 
 
Figure 5.40 A-P Dose Profile for the Spot scanning trial 2 lower spine field,  
measured in the sagittal Plane 
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Figure 5.41 S-I Dose Profile for the Spot scanning trial 2, measured in the coronal Plane 
 
 
 
Figure 5.42 S-I Dose Profile for the Spot scanning trial 2, measured in the sagittal Plane 
105 
 
 
Figure 5.43 R-L Dose Profile for the Spot scanning trial 3 upper spine field,  
measured in the coronal Plane 
 
 
Figure 5.44 R-L Dose Profile for the Spot scanning trial 3 lower spine field, 
measured in the coronal Plane 
106 
 
 
Figure 5.45 A-P Dose Profile for the Spot scanning trial 3 upper spine field,  
measured in the Sagittal Plane 
 
Figure 5.46 A-P Dose Profile for the Spot scanning trial 3 lower spine field,  
measured in the sagittal Plane 
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Figure 5.47 S-I Dose Profile for the Spot scanning trial 3, measured in the coronal Plane 
 
 
Figure 5.48 S-I Dose Profile for the Spot scanning trial 3, measured in the sagittal Plane 
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